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ABSTRACT 
Aziridinomitosenes (AZMs) are organic compounds structurally related to the 
mitomycins, a class of anti-tumor agents and antibiotics.  The cytotoxicity of the 
mitomycins is correlated to their ability to covalently link complimentary strands of 
DNA, forming DNA interstrand cross-links (ICLs).  Currently, there has been limited 
investigation into the biological activity of AZMs, likely due to difficulties in their 
synthesis.  Our lab has synthesized and evaluated the cellular effects of two AZMs, (1S, 
2S)-6-desmethyl(methylaziridino)mitosene (H/H-AZM) and (1S, 2S)-6-
methyl(methylaziridino)mitosene (Me/H-AZM).  We hypothesize that AZMs exhibit 
their cytotoxicity and cellular effects following a similar pathway to that of mitomycin C 
(MC), including the ability to form ICLs and modify DNA in cellular systems.  To test 
this hypothesis, we evaluated the cytotoxicity of our AZMs compared to MC in six 
cancer cell lines.  Previously, MC has also been shown to lead to the production of 
reactive oxygen species (ROS), activation of caspase enzymes, changes in mitochondrial 
membrane potential, and nuclear swelling.  As such, we probed for these effects in Jurkat 
and HeLa cancer cells upon AZM and MC treatment. Our studies reveal that the Me/H-
AZM has increased cytotoxicity compared to MC, while H/H-AZM was only more 
potent than MC in the T47D breast cancer cell line.  Both AZMs were more effective at 
increasing the levels of oxidative stress over MC.  Changes to the mitochondrial 
membrane potential were equivalent or greater than MC in treatments with both AZMs.  
Additionally, all three compounds were found to increase caspase-3 activation, with MC 
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leading to the greatest amount of activity in the Jurkat cell line.  Only MC treatment 
significantly increased caspase-3 activation in HeLa cells.  Both AZM and MC treatment 
stimulated nuclear swelling.  Finally, the DNA modifying-abilities of AZMs were 
investigated with the use of a Hoechst 33342 DNA cross-linking assay and a modified 
alkaline COMET assay.  Of the three compounds tested, these studies found that Me/H-
AZM lead to highest formation of DNA-DNA cross-links and modification to cellular 
DNA.  H/H-AZM treatment was found to produce a larger amount of cross-links and 
DNA modification in Jurkat cells than MC, but showed similar results to MC in HeLa 
cells.  Overall, AZMs were found to possess similarities to MC in their cellular effects in 
Jurkat and HeLa cells, with the ability to alkylate DNA in cell systems. 
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CHAPTER ONE: AZIRIDINOMITOSENES: A BRIEF HISTORY AND POTENTIAL 
AS ANTI-TUMOR CHEMOTHERAPEUTICS 
The mitomycins are a group of potent anti-tumor antibiotics originally isolated in 
1956 by Japanese researchers from the soil bacteria Streptomyces caespitosus.1 The 
search for new anti-tumor agents led the initial discovery of mitomycin A (MA) and 
mitomycin B (MB); this was soon followed by the isolation of the clinically relevant, 
mitomycin C (MC) from the same bacterial strain (Figure 1.1).1-3 Four years later, an N-
methylated version of MC, porfiromycin, was isolated from fermentation broths of 
Streptomyces ardus in 1960.4   
 
Figure 1.1 Structural representations of mitomycin A, B, and C. 
Several detailed reviews have been published that discuss the reactivity and 
biochemistry of mitomycins and MC analogs.5-11  In addition, reviews have been 
published outlining several approaches to the complete synthesis of mitomycins and 
mitomycin derivatives, “mitomycinoids”.6,12  This review is unique in the fact that it will 
attempt to focus primarily on aziridinomitosenes (AZMs) and their biological activity.  
To put this into perspective, an initial discussion regarding the structural skeletons of the 
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mitomycins and AZMs will be presented.  From here, the isolation and initial biological 
activities of MC will be lightly reviewed, followed by a brief overview of the clinical 
utilization.  A general discussion of MC affiliated DNA alkylation, oxidative stress, and 
anaerobic preference will conclude the discussion of MC.  An overview into work with 
AZMs will then ensue, focusing on biological activity studies, DNA alkylation 
properties, and analogs with biological investigations.  To finish, a brief outline to the 
potential benefits and drawbacks foreseen in AZM biological activity and development 
will be given.  
Overview of Mitomycin and Aziridinomitosene Structural Skeleton 
In 1962, Webb and coworkers resolved the structures of MA, MB, MC, and 
porfiromycin.13,14  Confirmation of the chemically devised structure of MA was achieved 
through X-ray crystallography the same year.15  These mitomycins were found to contain 
a tetracyclic core comprised of a fused pyrrolo[1,2-a]indole ring system, an aziridine, and 
carbamate functional group.10-15  Since the initial discoveries of MA, MB, MC, and 
porfiromycin, numerous other mitomycin analogues have been isolated or synthesized, 
each containing the same core structural backbone.10-12 The mitomycins have thus been 
grouped into three primary classes (A-type, B-type, and G-type) based on the substituents 
extending from the tetracyclic core (Figure 1.2).6,10,12 
 
Figure 1.2 Structures of A-type, B-type, and G-type mitomycins.6,12 
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In 1963, Iyer and Szybalski found that MC was capable of covalently linking 
complimentary strands of DNA, forming a DNA interstrand cross-link (ICL).  Iyer and 
Szybalski proposed that a reductive activation cascade of mitomycins resulting in DNA 
alkylation, which included the formation of a reduced aziridinomitosene 
(leucoaziridinomitosene) as a reactive intermediate was proposed (Figure 1.3).17-19   Later 
work presented discussed that cross-linking efficiency of AZMs increased in the presence 
of reducing agents, supporting the assertion that the reduced AZM is the most active form 
of mitomycins.18  
 
Figure 1.3 Structures of MC and leucoaziridinomitosene (reduced AZM).19 
The first AZMs were characterized as degradation products of their parent 
mitomycins in the mid-1960s (Figure 1.4).21  AZM synthesis was accomplished through 
the conversion of N-methylmitomycin A (NMA) and mitomycin B (MB) to their 
corresponding AZMs NMA-AZM and MB-AZM, respectively.  This was accomplished 
via catalytic hydrogenation in N,N-dimethylformamide (DMF) at atmospheric pressure, 
followed by reoxidation at reduced pressure, trituration, and recrystallization.21  
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Figure 1.4 Structural representations of N-methyl mitomycin A (NMA) and 
mitomycin B (MB) with their corresponding aziridinomitosenes.21  
Structurally, mitomycins and AZMs share the same core backbone, including the 
presence of a tetracyclic core arranged in a 6-5-5-3 motif, with the six and three 
membered rings presenting as a quinone and aziridine moiety, respectively.16  The key 
difference in designation as a mitosane (core of mitomycins) versus an aziridinomitosene 
occurs between C9 and C9a where mitosanes have a single bond, and AZMs maintain a 
double bond (Figure 1.5).10   
 
Figure 1.5 Structural depictions of MC and mitomycin C aziridinomitosene 
(MC-AZM) with partial carbon numbering scheme.  
Mitomycin Isolation and Initial Studies into Biological Activity  
Preliminary evaluations of purified mitomycin A, B, and C and their biological 
activities found these species to exhibit strong bactericidal and anti-tumor properties.1-3  
Mitomycins were found to exhibit broad spectrum antibiotic action against both gram 
positive and gram negative bacteria.  MA was shown to be the most potent.  Despite the 
5 
 
broad range of bacterial toxicity, effectiveness against fungi and streptomycetes was 
limited.1-4 
Initial in vivo experiments into the anti-tumor actions of MA and MB were 
conducted on mice inoculated with Ehrlich ascites carcinoma.  Upon confirmation of 
tumor growth, intraperitoneal injections of mitomycins were given at various 
concentrations.  Three days post drug injection, tumor cells were counted and compared 
to the untreated group as the average days of life prolongation.  This study found that 
mitomycin injections were able to completely abolish tumor cells, extending life up to 11 
days longer than untreated mice.1  Isolation of MC from the same bacterial broth was 
completed and followed with preliminary evaluations into its biological activity by 
Wakaki and co-workers.3  Treatments of mice inoculated with Ehrlich ascites carcinoma 
showed that MC exhibited anti-tumor properties similar to MA and MB.  However, drug 
toxicity was also demonstrated to be a problem as MC was demonstrated to cause death 
in mice 2-14 days post injection.3 
Mitomycin C Clinical Use 
Of the mitomycins, MC has received the most investigation and clinical use.2,7,22  
For further information regarding the clinical applications of mitomycin C, please see the 
reviews referenced.22-26   
Mitomycin C has been utilized as a single agent or in combination with other 
chemotherapeutics.  Originally MC was found to be useful in the treatment of several 
carcinomas, including those of the cervix, lungs, head and neck, breast, pancreas, colon, 
and rectum.27 Clinical utilization of MC was linked to several side effects, including 
myelosuppression leading to leukopenia and thrombocytopenia. More seriously, the 
6 
 
possibility of renal failure that manifests even after discontinued treatment was 
reported.25,27  Due to these side effects, the clinical use of MC was largely discontinued.  
However, MC continues to have high activity in localized treatment of bladder cancer.23 
In addition to its use as a chemotherapeutic agent, the anti-proliferative properties 
of MC have found roles in other fields of medicine, including surgical and ophthalmic 
specialties.  In ocular surgeries, MC is typically applied topically to promote the 
reduction of scarring and inhibition of the wound healing process, leading to prevention 
of haze.26,28  The anti-proliferative effects of MC on keloid fibroblasts have led to use as 
an adjunct therapy in the prevention of recurring highly collagenous hypertrophic and 
keloid scars.29,30 After surgical removal of the scar, application of MC to the surgical 
wound was demonstrated to decrease recurrence of keloid tissue.30  Furthermore, reports 
of MC’s potential use in otolaryngolic surgeries has been investigated in rabbits for 
successful use in decreasing the closure rate of maxillary sinus antrostomies.31 
Mitomycin DNA Alkylation 
In the 1960s, studies in the mitomycins biological activity revealed the formation 
of ICLs, with increased ICL formation occurring in species possessing greater G-C bases 
in their DNA.17-19 Mitomycins were found to further inhibit DNA synthesis through 
additional DNA alkylating events, including mono-alkylation and intrastrand cross-
linking.32  Nine different MC-DNA adducts have been isolated and characterized from 
MC treated cancer cells (Figure 1.6).   The isolated adducts include six different mono-
alkylation and three bis-alkylated species, resulting from MC or its major cellular 
metabolite, 2,7-diaminomitosene (DAM).7,11,32-38  
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  Mono-adducts   Bis-adducts 
1 1,2-trans-deoxyguanosine monoadduct 6 N2 2,7-diaminomitosene monoadduct 
2 1,2-cis-deoxyguanosine monoadduct 7 dG-dG intrastrand cross-link 
3 1,2-trans-deoxyguanosine decarbamoyl monoadduct 8 1,2-trans-dG-dG interstrand cross-link 
4 1,2-cis-deoxyguanosine decarbamoyl monoadduct 9 1,2-cis-dG-dG interstrand cross-link 
5 N7 2,7-diaminomitosene monoadduct     
Figure 1.6 Structures of nine characterized DNA adducts resulting from MC 
treatment.11,32 
The formation of ICLs is considered the main cause of cellular toxicity.   ICLs are 
extremely potent, with the ability to produce cell death with as little as one cross-link per 
genome.17-20   The mitomycins ability to form ICLs revealed that covalent linkage of 
complementary strands occurred only in the presence of cell lysates or other exogenous 
reductants, thus suggesting that mitomycins must first undergo reductive activation prior 
to formation of the lethal DNA cross-links.17-19  
Mitomycin reduction can occur via one or two electron reduction processes 
initiated through enzymatic or chemical means.  Chemically, MC has been shown to 
become reductively activated by thiols, dithiols, ascorbic acid, formate radicals, sodium 
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borohydride, sodium dithionite, and platinum catalyzed hydrogenation.19,39-41  In addition 
to the previous chemicals, reductive activation of MC has been reported to occur 
appreciably through an acid catalyzed pathway at a pH < 5.42  Two electron reduction of 
MC is accomplished by DT-diaphorase, yielding the hydroquinone mitomycin.43  The 
most common enzyme catalyzed reduction occurs via one electron by NADPH-
cytochrome P-450 reductase, xanthine oxidase, NAD(P)H-cytochrome c reductase, 
xanthine dehydrogenase, and NADH-cytochrome b5 reductase.11,43-45   
Upon discovering that mitomycins must first be reductively activated, Iyer and 
Szybalski suggested a preliminary reduction pathway using the resonant forms of 
mitomycins (Figure 1.7).17-19  Briefly, their proposal began with a reduction of the 
quinone ring (1) to a hydroquinone moiety (2), followed by an elimination of the 
methoxy (hydroxyl) group at carbon 9a (3), and proton removal from carbon 9.  This 
results in the formation of an aromatic indole system (4).17,18  
 
Figure 1.7 Reductive activation of mitomycins presented by Iyer and Szybalski.18 
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Further inquiry into the mechanism of reductive activation has afforded the most 
widely accepted pathway towards activation of C1 and C10 for DNA alkylation (Figure 
1.8), presented by the Tomasz research group in 1997.32  This pathway includes the 
formation of mono and bis-alkylated species and reduction via one or two electron routes.  
Initial reduction of the mitomycin quinone (MC) can occur via one or two electrons 
yielding a semiquinone (5) or a hydroquinone (6), respectively.  
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Figure 1.8 Mitomycin C reductive activation cascade leading to mono and bis-
alkylation.  The blue sphere acts as the first nucleophile, whereas the red sphere is 
the second nucleophile completing the DNA interstrand cross-link.11,32 
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From the hydroquinone (6), elimination of the methoxy group (7) occurs via 
formation of an N4 iminium intermediate (8).  Deprotonation at C9 leads to formation of 
the leucoaziridinomitosene (9).  At this point, the leucoaziridinomitosene can continue 
towards formation of a bis-adduct or undergo mono-alkylation.  In route to creating the 
interstrand cross-link, the leucoaziridinomitosene (9) is protonated to form the 
aziridinium (10).   The resonance stabilized aziridine ring opening occurs at C1, forming 
a quinone methide (12), via 11.  From here, nucleophilic attack of the exocyclic amino 
group of guanosine, as represented by the blue sphere, upon C1 of 12 leads to the first 
DNA alkylation event (13).  After alkylation at C1, elimination of the carbamate group 
(14) produces the second electrophilic site on C10.  The second alkylation event occurs 
through nucleophilic addition of the complimentary strand’s guanine exocyclic N2 amino 
group (red sphere) producing the bis-alkylated DNA adduct (15).  Subsequent oxidation 
of the hydroquinone to the quinone produces the final mitomycin-DNA interstrand cross-
link (16), which have been characterized by HPLC and LC-MS/MS analysis.7,10-12,32,37 
Mitomycin C Oxidative Stress 
Quinone containing compounds that are capable of undergoing one or two 
electron redox processes, such as MC, can lead to the increased production of reactive 
oxygen species (ROS) in the presence of molecular oxygen.46 ROS play integral roles in 
the normal physiological processes of cells at normal levels, including cell signaling and 
combating infectious agents.47  At elevated levels, ROS participate in oxidative stress or 
damage intracellularly, leading to disruption of normal function and potential damage to 
lipids, DNA, mitochondria, and proteins.47-49  The quinone-containing mitomycins 
undergo this one or two electron reduction with several oxidoreductase enzymes in route 
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to alkylating DNA.  Inquisitions into the MC related increase in chromosomal 
abberations, chromatid rearrangements and fragmentations, and additional DNA damage 
were directed towards the drug induced production of ROS and its relationship to these 
effects.17,56,57 
Early in vitro studies into the mitomycin-mediated formation of ROS identified 
the generation of hydrogen peroxide, hydroxyl radicals, and superoxide anion by reduced 
MC (Figure 1.9).52-58  Identification of MC induced superoxide anion was conducted 
using sulfite oxidation in microsome NADPH oxidase systems.52  Through inhibition of 
sulfite oxidation in the presence of superoxide dismutase, superoxide anion was identified 
as a result of MC reduction in the presence of oxygen.52  Additional evidence to the 
mitomycin catalyzed superoxide production was conducted using electron spin resonance 
(ESR) and the spin trapping reagent N-tert-butyl-α-phenylnitrone.54 The identity of each 
species was determined with the addition of catalase and superoxide dismutase to the 
reaction mixture, leading to a loss of the spin trap nitroxide radical.  These results further 
indicated that reduced MB and MC produce superoxide anion and hydrogen peroxide.54  
Both MC and a MC-DNA complex were found to generate hydrogen peroxide after 
reduction followed by exposure to air.  Hydrogen peroxide levels were abolished upon 
addition of catalase to the reaction mixture of both MC species, confirming the identity of 
the ROS as H2O2.53  Characterization of hydroxyl radical formed by enzymatically 
reduced MC was conducted using ESR and a spin trapping agent.51,55  Hydroxyl radical 
identification was confirmed using the addition of superoxide dismutase and catalase, as 
well as the formation of ethylene from methional.55  The generation of ROS through 
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reduced MC was found to lead to the induction of single strand cleavages in PM2 
covalently closed circular DNA, thyroid, plasmid, and λ DNA.50,51 
 
Figure 1.9 Schematic of MC induced ROS production. One or two electron 
reduced MC leads to the production of superoxide anion or hydrogen peroxide in 
the presence of molecular oxygen.8 
Exploration into the correlations between cytotoxicity of mitomycins and the 
production of ROS was investigated using cellular systems. Comparisons of four 
mitomycin compounds (MC, porfiromycin, BMY-25282, and BL-6783) and their 
associative cytotoxicity were conducted in EMT6 tumor cells under an aerobic 
environment (Figure 1.10).59 Using EMT6 cell sonicates, NADPH-cytochrome c 
reductase, xanthine oxidase, and bovine heart mitochondria as biological reduction 
systems, the consumption of oxygen by the four compounds was measured.  In aerobic 
conditions, BMY-25282 and BL-6783 displayed increased toxicity over both MC and 
porfiromycin.  Generation of both hydroxyl and superoxide radicals were greater for 
BMY-25282 and BL-6783 than MC and porfiromycin in three of the four reduction 
conditions, providing indications that enhanced aerobic toxicity is likely affiliated with 
increased production of ROS by mitomycins.59 
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Figure 1.10 Structural depictions of mitomycin analogs: BMY-25282, BL-6783, 
BMY-43324.59,63 
Experiments conducted with VA-13 and IMR-90 human embryonic cells 
provided additional insight into the role of ROS.60  Specifically, VA-13 cells, which are 
more sensitive to oxygen radical production than are IMR-90 cells, were more 
susceptible to MC treatment.  A similar frequency in cross-linking was displayed 
between cell lines, although increased levels of double strand DNA breaks were observed 
in VA-13 cells. Pre-incubation with superoxide dismutase or catalase led to an increased 
survival of VA-13 cells upon treatment with MC but not in IMR-90 cells, suggesting that 
sensitivity to MC treatment could be correlated with the ability to neutralize ROS.60  
Mitomycin Anaerobic Preference 
In the presence of molecular oxygen, reductive activation of MC is halted, 
returning it back to the inactive quinone form.17-19, 56-57  This subsequent reduction-
oxidation pathway renders MC less potent in O2 rich environments, decreasing the ability 
to form ICLs, with increased production of reactive oxygen species.61  As a result, in the 
early 1980s, the potential of MC as a selective hypoxic anti-tumoral drug was 
investigated.  Measurements of MC metabolism (the rate of MC disappearance and 
formation of an alkylating species) were conducted in EMT6 and S-180 cell sonicates 
under hypoxic and aerobic conditions.  These studies found that the rate of MC 
metabolism was much greater under hypoxia than in the presence of oxygen. 
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Additionally, EMT6 cells treated with MC anaerobically exhibited increased sensitivity 
to the drug.61 Investigations were expanded into the exploration of porfiromycin 
cytotoxicity to EMT6 cells under anaerobic and aerobic conditions.  Porfiromycin 
displayed similar cytotoxicity to MC under hypoxia, but had diminished activity 
compared to MC towards EMT6 cells in the presence of oxygen, establishing the notion 
that MC and porfiromycin are selective hypoxic agents.62   
Mitomycin analogues BMY-25282, BMY-43324, and BL-6783 were evaluated 
for their preference to anaerobic versus aerobic environments in EMT6 cells (Figure 
1.10). BMY-43324 displayed hypoxic preference, with greater cytotoxicity and cross-link 
formation than MC and porfiromycin.  BL-6783 experienced no difference in toxicity 
under hypoxic or aerobic conditions.  Under aerobic conditions, BMY-25282 displayed 
an increased potency and earliest formation of DNA cross-linking.  Structural analysis 
(MC vs. porfiromycin; BMY-25282 vs. BL-6783) with ICL formation and cell killing 
ability revealed that methylation of the aziridine nitrogen leads to a preference towards 
hypoxic conditions.63 
Mitomycin C Resistance 
Effective MC treatment relies upon tumors that are high in flavin reductases and 
other proteins that activate mitomycins.8  Inspections into the cytotoxic resistance of 
mitomycin producing Streptomyces lavendulae identified two genes (mcrA and mcrB) 
responsible for coding the protein MCRA (mitomycin C resistance associated).   This 
protein contains a covalently linked FAD, assisting in the reoxidation of hydroquinone 
mitomycin C to the quinone moiety in the presence of oxygen. Sequential analysis of 
MCRA revealed similarities to oxygen oxidoreductases in animal, plant, and bacterial 
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organisms.64,65  Expression of the mcrA gene into CHO cells lead to a substantial 
increased resistance to mitomycin C and porfiromycin under aerobic conditions.  When 
treated under hypoxic conditions, a slight increase in resistance was observed in the 
MCRA-1 expressing CHO cells.  MCRA and its sequential relationship to oxygen 
oxidoreductase enzymes in animal cells generates a plausible stance that tumor cells 
exhibiting overexpression of these enzymes could lead to increased resistance to MC.  
  The necessity of biological reduction to form ICLs allows for the ability to 
develop resistance to mitomycin treatment.  Multiple cancer cells lines have been shown 
to exhibit resistance to MC, in accordance with the regulation of several bioactivating 
enzymes, including DT-diaphorase and NADPH:cytochrome c oxidoreductase.66-68 The 
ability to re-establish MC sensitivity was displayed in CHO cells expressing the MC 
resistant MCRA protein through overexpression of DT-diaphorase and 
NADPH:cytochrome c oxidoreductase.68    
Attempts to profile genes involved in MC resistance were carried out through 
nonessential gene deletions in Saccharomyces cerevisiae.  Deletions of genes involved in 
nucleotide excision repair, including damage recognition (RAD14 and RAD4) and 
incision endonucleases (Radp1-Rad10p complex and Rad2p) led to an increased 
sensitivity of MC.  Further increased sensitivity to MC was observed upon deletion of the 
PSO2/SNM1 gene, which is involved in the repair of interstrand cross-links.  Lastly, the 
removal of multiple DNA damage checkpoint genes led to an increase in yeast’s 
sensitivity to MC.69 
Successful utilization of MC moving forward appears to be dependent on a 
variety of aforementioned factors.  These factors include the enzymatic profile of cells, 
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their ability to reduce MC, and presence of resistant genes.  For these reasons, future uses 
of MC as an effective treatment option may require tailoring to the appropriate system.   
Aziridinomitosene Biological Activity 
Investigations into the biological activity of AZMs have been limited in 
comparison to the mitomycins.  The inaugural explorations into the biological activity of 
AZMs were conducted through the conversion of MB and NMA to their respective 
AZMs (Figure 4).21,70-74  In vitro examinations revealed that NMA-AZM and MB-AZM 
exhibit powerful broad spectrum bactericidal agent in accordance with the mitomycins, 
while showing additional activity in mice orally and subcutaneously against 
Staphylococcus aureus and Streptococcus pyogenes C-203.21 
In 1971, Kinoshita and co-workers studied the biological activity of the five 
AZMs depicted in Figure 1.11.  Evaluations of the bactericidal and anti-tumor activity of 
NMA-AZM and multiple mitosene compounds demonstrated that the most active 
compounds contained the three functional groups: an aziridine ring, carbamate, and 
quinone.  NMA-AZM displayed activity against gram positive and gram negative 
bacteria, while also demonstrating high anti-tumor activity against solid sarcoma 
180.21,72-74  
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Figure 1.11 Structures of aziridinomitosenes studied by Kinoshita and co-
workers.72 
The other AZMs (17, 18, 19, POR-AZM) were evaluated for their bactericidal 
properties against gram positive and gram negative bacteria, but not for their anti-tumoral 
activity.  Of these, 18 (7-dimethylamine) displayed similar activity against gram positive 
bacteria to NMA-AZM, with decreased efficacy towards gram negative bacteria.  POR-
AZM and 19 showed little efficacy as a bactericidal.72 
Hodges and Remers evaluated the biological activity of NMA-AZM in P-388 
murine leukemia with several other mitosene analogs with various substitutions about 
carbon 1.73  Their studies found that NMA-AZM was more effective at prolonging life in 
treated mice over those treated with any of the 1-substituted mitosenes.  When compared 
to MC, NMA-AZM was found to have a higher optimal dose at 12.8 mg/kg versus that of 
3.2 mg/kg for MC.  However, NMA-AZM was found to be more effective at increasing 
the life span of treated mice, despite its requirement for higher dosages.73 
The synthesis and subsequent anti-tumor activity against P-388 leukemia in mice 
of ten different 7-substituted AZMs was conducted by Iyengar, Remers, and Bradner 
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(Figure 1.12).74 Several of the synthetic AZMs showed activity against the murine tumors 
comparable to MC, but required higher dosages. The most active AZMs, NMA-AZM, 
and 25 were both successful at prolonging the life span of treated mice over that of MC.  
The observed increase in survival time required four and eight fold greater dosages, 
respectively.  AZM 21 provided the only mice surviving to 30 days after treatment, in 
two dosages, both of which were higher than MC (8x and 16x). Furthermore, activity was 
seen at high dosages by 22 and 26; there was not an observed increase in survival times 
compared to MC treated mice. 74    
 
Figure 1.12 Structural representations of 7-substituted aziridinomitosenes.74 
Investigations into the range of activity displayed the 7-substituted AZMs was 
conducted by testing MC-AZM, 22, 23, and MC against mice inoculated with L-120 
murine leukemia.  Activity was seen in two of the compounds (AZM 22 and 23), but not 
to the extent of MC.  Of particular interest was the inactivity MC-AZM, as it is an 
intermediate in the DNA alkylation pathway and would have thought to present as an 
active compound.74   
Additional analysis into the biological activity exhibited by the 7-substituted 
AZMs was an assessment of the structural elements leading to increased potency.  A key 
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distinguishing feature between the two sets of AZMs is the presence of a methylated 
aziridine ring in NMA-AZM, POR-AZM, 25, and 26.  This was found to increase the 
activity of the carbon 7-substituted AZMs in accordance with the calculation of a 
minimum effective dose (MED), the minimum dose to exhibit a response.  Explanations 
into the increased activity observed by N-methylated AZMs were attributed to the 
increased basicity of the aziridine.  Protonation of the aziridine ring leads to activation 
and ring opening, followed by subsequent nucleophilic addition at C1.  Therefore, a 
methylated aziridine ring would have increased basicity when compared to the 
hydrogenated version, leading to greater anti-tumoral activity in AZMs. 74  In addition, 
the presence of the aziridine ring functional group was affiliated with the ability to 
prolong life by NMA-AZM treated mice inoculated with P-388 leukemia.73 
Several AZMs have displayed biological activity with most requiring elevated 
quantities above MC in order to elicit similar responses.  Despite the increased dosages, 
treatment with some AZMs resulted in the prolongation of life.  Further, the increased 
activity of methylated AZMs suggests that synthetic efforts should consider incorporating 
this functional group into their architecture. 
Aziridinomitosene DNA Alkylation 
Formation of DNA ICLs have been attributed as the main cause of the 
cytotoxicity associated with mitomycins.20,33  Exploration into the pathway through which 
mitomycins generate ICLs, incorporates AZMs as intermediates towards DNA 
alkylation.32  Investigations in DNA modification of AZMs began with AZMs, which 
were converted from their parent mitomycins through reduction-oxidation reactions and 
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DNA (Figure 1.13).75,76  Soon after, evaluations of a C6/C7 unsubustituted synthetic 
AZM (H/H-AZM) and its ability to covalently modify DNA were investigated.77,78  
 
Figure 1.13 Structure of AZMs investigated for DNA alkylating properties. NMA-
AZM, MC-AZM, and (1S, 2S)-6-desmethyl(methylaziridino)mitosene (H/H-
AZM).75-79 
Teng and coworkers conducted an in vitro ICL analysis using MC, NMA, and 
NMA-AZM under hypoxic conditions in the presence of the reducing agent sodium 
dithionite and radiolabeled DNA.75 Results showed that NMA-AZM exhibits a sequence 
selectivity towards 5'-XCpGY, similar to NMA and MC, while cross-link formation by 
NMA-AZM occurred at higher percentage towards the 5'-XCpGY-3' motif than MC at 
pH 4.5 and 7.5, with similar frequency in 5'-XGpCY-3' sequences.  The cross-link 
percentages for NMA-AZM were consistent with that of its parent mitomycin, NMA, 
throughout the study.75 
Additional studies into AZM DNA alkylation were conducted using the UvrABC 
assay in the absence of a reducing agent, with NMA-AZM and MC-AZM.76 Under non-
reducing conditions, AZMs displayed similar sequence specificity to reduced MC, 
bonding preferentially to the 5'-CpG site, with alkylation occurring at the guanine 
residue, as in the previous study.75,76  Furthermore, upon reductive activation of NMA-
AZM with sodium dithionite, a decline of sequence selectivity of DNA alkylation was 
observed, suggesting an increase in the reactivity of this species.76 
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The DNA modifying capabilities of the C6/C7 unsubstituted AZM, (1S, 2S)-6-
desmethyl(methylaziridino)mitosene (H/H-AZM), were also evaluated using the 
UvrABC assay.78  In the absence of reducing agent, H/H-AZM formed DNA cross-links 
with selectivity towards both 5'-CpG and 5'-TpG sequences, with modifications occurring 
at guanine residues.  Cross-linking with H/H-AZM was shown to be time dependent with 
increased formation at longer incubation times ranging from 1-4 hours. In addition to the 
DNA modifying properties of H/H-AZM, evidence was provided that H/H-AZM could 
be forming DNA-protein cross-links (DPCs).  Formation of DPCs is highly likely given 
the electrophilic sites located at carbon 6 and carbon 7, in addition to the traditional C1 
and C10 locations of DNA alkylation in mitomycins.78 
DNA binding studies with H/H-AZM were conducted in vitro with the absence of 
exogenous reductants under aerobic conditions, revealing formation of DNA ICLs with 
preference to a 5'-CpG motif.79  The cross-linking ability was evaluated as a function of 
pH from 5-7.5, exhibiting the largest formation of ICLs at pH 6.0.  These results appear 
to be consistent with the increased toxicity displayed by MC in acidic environments.  
Alterations in the levels of interstrand cross-linking were seen based on the nucleotide 
immediately preceding and following the 5'-CpG sequence, with the highest ICL 
formation occurring in the presence of the tetranucleotide sequence of 5’-ACGT.  
Replacement of 2'-deoxyguanosine for 2'-deoxyinosine, led to abolishment of cross-link 
formation, confirming the critical role the exocyclic amino group of 2'-deoxyguanosine in 
ICL formation.79 
These studies provide direct evidence that AZMs are capable of forming DNA 
ICLs, and do so with similar properties to MC.  AZM-induced ICL formation was found 
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to follow the same sequence specificity of MC with preference towards 5'-CpG-3' motifs.   
Furthermore, DNA alkylation was found to occur at the guanine residues, as displayed by 
MC.  DNA modification by AZMs has been shown to occur with similar frequency as 
MC, in the presence and absence of exogenous reductants, proposing that formation of 
AZM DNA adducts may not require reductive activation.  
Aziridinomitosene Analogs 
A number of AZM analogues have been synthesized but little on their biological 
activities have been published to date (Figure 1.14).  In 1996, an analog to the MA AZM 
was synthesized by the Jimenez group.  The synthesis started with nitration of 2,5-
dimethylanisole.  Their final product (27) lacked a carbamate functional group, and a 
functional group at the C10 position altogether.80  Soon after, a fully functional MA AZM 
was synthesized, containing both the aziridine ring and carbamate groups.81 
Following this reports of a successful synthesis of a tetracyclic model for an 
aziridinomitosene, via an 11 step synthesis were published.82  This process originated 
with the D-erythronolactone derivative (-)-2,3-O-isopropylidene-D-erythronolactone.  
The final two products consisted of the aziridinomitosene analog possessing an ester at 
C10, with an unprotected aziridine (28) or the N-phosphorylated analog (29).82 
24 
 
 
Figure 1.14 Structures of synthetic AZM analogs.80,82,83 
Later, Wiedner and co-workers synthesized two protected (N-trityl (30) and N-
TBDPS (31)) derivatives of the AZM version of FK317, and evaluated their ability to 
undergo solvolysis at carbons 1 and 10.83  Under mild nucleophilic conditions, the 
analogues 30 and 31 exhibited a faster heterolysis at C10 than C1.  This observation 
presents with conflicted behavior to that of typical AZMs containing the stabilizing 
quinone ring, creating C1 as the preferential electrophile to nucleophilic attack.83 
In 2011, Bonham and co-workers successfully synthesized a diazole analogue 
(32) of an aziridinomitosene, fusing an aziridine ring onto a pyrrolo[1,2-a]benzimidazole, 
and evaluated its biological activity (Figure 1.15).  An additional heterocyclic system, N-
[(1-tritylazridin-(2S)-yl)methyl]-1H-benzimidazole (33) was also synthesized and studied 
in this report.  The cytotoxicity of these compounds were evaluated against MC in three 
cell lines, GM00637 (human normal skin fibroblasts) and two human breast cancer cell 
lines (MCF-7 and HCC1937 (BCRA1 deficient)).84 
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Figure 1.15 Structural representations of synthetic AZM analogs 32 and 33.  
Aziridine ring fused onto a pyrrolo[1,2-a]benzimidazole (32) N-[(1-tritylazridin-
(2S)-yl)methyl]-1H-benzimidazole (33).84 
The synthetic compounds 32 and 33 showed lower toxicity in the GM00637 cell 
lines than MC with IC50 values of 3.11 ± 0.44, 1.26 ± 0.13, and 0.77 ± 0.18 µM 
respectively, while 33 displayed the largest potency over 32 and MC in MCF-7 cells with 
a IC50 of 0.22 ± 0.04, 0.84 ± 0.14, and 0.93 ± 0.11 µM, respectively.   In HCC1937 cells, 
MC was the most potent with an IC50 value of 0.03 ± 0.01 µM, followed by 33 (0.16 ± 
0.03 µM), and finally 32 (0.67 ± 0.01 µM).  Both analogs have preferential toxicity 
towards breast cancer cell lines (MCF-7 and HCC1937) over that of normal human skin 
fibroblasts (GM00637).84 
Aziridinomitosenes: Potential Problems 
To date, there has been very limited investigations into aziridinomitosenes and 
their potential biological activity when compared to the mitomycins.  Most of the 
exploration has been oriented towards AZMs derived from the conversion of the parent 
mitomycin, somewhat restricting functionalization and potential improvements in the 
cytotoxicity of the molecules.  One likely main cause of the deficiency in attention is due 
to the difficulty in synthesizing AZMs and their analogs while maintaining functionality, 
natural substitution pattern about the tetracyclic core, and correct stereochemistry.77,82  
The presence of the double bond between carbons 9 and 9a allows for allylic like 
stabilization of carbon 1 upon opening of the aziridine ring.  This intermediate occurs in 
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the reductive activation of mitomycins and their path towards DNA alkylation.  In the 
case of AZMs, it produces a reactive species capable of readily undergoing 
solvolysis.71,77  Han and Kohn showed that AZMs derived from MC and porfiromycin 
undergo methanolysis with half-lives as low as three and fourteen minutes at a pH of 7.0, 
respectively.71  Similar studies were conducted with H/H-AZM at 20 ºC and at a pH of 
7.0, the half-life was found to be 2,000 minutes, over 660 fold greater than MC-AZM.78  
The major deviation in observed half-life was stated to likely be attributed to the presence 
of the electron donating amine present at C7 of MC-AZM and POR-AZM.  Increased 
electron density within the indoloquinone system presumably assists in stabilizing 
carbocation formation at C1, leading to increased reactivity and susceptibility to 
solvolysis.78    
In addition to the difficulties presented in synthesizing AZMs, their biological 
activities have shown promise but have not yet been shown to surpass that demonstrated 
by MA or MC.  Several AZMs have displayed bactericidal activity and anti-tumoral 
properties similar to the mitomycins.  Despite this similar activity, the efficacy of AZMs 
investigated required larger dosages than MC or MA to exhibit a similar response.21,72-74   
Potential Benefits of Aziridinomitosenes over Mitomycins 
DNA alkylation by MC is reliant upon reductive activation; AZMs do not share 
this requirement in their ability to alkylate DNA, presumably affording AZMs an 
advantage as a DNA modifying agent.17-19  Decreased sensitivity to MC has been 
documented in cells lines lacking or expressing decreased levels of oxidoreductase 
enzymes acting in the reductive activation cascade of MC.66-68 As such, mutations or 
alterations in cancer cells can lead to changes in the successful utilization of MC, 
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rendering tumors more or less sensitive to treatment based on the expression of these 
reductive activation enzymes.  AZM activity may not rely upon the levels of these 
enzymes, establishing the hypothesis that they may be more efficacious with decreased 
dependency on oxidoreductase enzymes in their biological activity. Furthermore, 
investigations into AZM DNA alkylation produced similar frequencies in the ICL 
formation under aerobic conditions.  This may lead to a broad spectrum anti-tumoral 
agent that can be applied to several environments, rather than acting as a selective 
hypoxic agent like MC. 
Studies with substitutions at C7 within MA and MC have presented evidence that 
increased lipophilicity leads to more cytotoxic compounds.85  The ability to fine tune 
functional groups at C6, C7, and C10 within AZMs presents with the potential to create 
compounds with a more facile ability to traverse cellular membranes and increase 
stability of the electrophilic carbons, and potentially rendering them more potent.   
Concluding Remarks 
Multiple AZMs have been found to exert antibiotic and anti-tumoral activities 
similar to mitomycins.  Of particular interest is an observed prolongation of life in mice 
treated with three AZM analogs over that of those that were MC treated.  Regeneration in 
the interest of AZMs could prove to be valuable in the search for new antibiotics or 
chemotherapeutic agents with a decrease in serious side effects.  Despite the difficulties 
faced in synthesizing these compounds, there have been many successful attempts in 
producing AZMs.  Their efforts allow for further modification and “fine-tuning” to 
enhance AZM biological activity.  Moving forward, a focus should be directed towards 
enhancing the lipophilicity of AZMs for enhanced cellular uptake, the steric and 
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electronic effects of substituents located at C6 and C7, and methylation of the aziridine 
nitrogen.  
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CHAPTER TWO: MECHANISMS OF AZIRIDINOMITOSENE CYTOTOXICITY 
Two synthetic aziridinomitosenes (AZMs) were evaluated for their cytotoxicity in 
six human cancer cell lines, and the cellular effects compared to mitomycin C (MC).  
Me/H-AZM was found to be a more potent cytotoxic agent than either H/H-AZM or MC.  
H/H-AZM was the least cytotoxic of the three drugs, although it displayed increased 
potency over MC in the T47D cell lines.  Several cellular effects of AZM and MC 
treatment were investigated in Jurkat and HeLa cell lines.  Treatment with either AZMs 
increased intracellular oxidative stress relative to MC treatment, with H/H-AZM showing 
the greatest overall increase.  Pre-treatment of Jurkat cell cultures with the antioxidant N-
acetyl-L-cysteine (NAC) resulted in a measurable decrease of H/H-AZM cytotoxicity and 
no measurable changes in Me/H-AZM or MC cytotoxicity, suggesting that under the 
conditions tested H/H-AZM may work through increasing oxidative stress, while the 
primary cytotoxic effect of MC and Me/H-AZM was probably not mediated through 
increased oxidant stress. In HeLa cells, pretreatment with NAC produced a measurable 
increase in Me/H-AZM with no alterations observed in MC treatments.  However, 
treatment of Jurkat or HeLa cell lines with any of the three drugs did produce a collapse 
in the mitochondrial membrane potential, with Me/H-AZM inducing the largest 
disruption.  Apoptotic cell death was evaluated by measuring drug induced activation of 
caspase-3, by H/H-AZM, Me/H-AZM, or MC.  In Jurkat cells, all three drugs were 
active, with MC treatment causing the largest activation of caspase-3.  In HeLa cells, 
only MC treatments led to significant caspase-3 activation.  Fluorescence microscopy of 
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MC, H/H-AZM, and Me/H-AZM treated cells showed the drugs also produced changes 
in nuclear morphology.  All three drugs produced increased nuclear size in HeLa cells in 
at least one of the tested drug concentrations that were consistent with stimulating a 
necrotic, rather than apoptotic response.  The results of these studies indicate that AZMs 
and MC share similarities in their cellular effects including the induction of 
mitochondrial membrane changes, activation of caspase-3, and stimulation of nuclear 
swelling.  Furthermore, the two AZMs investigated display increased toxicity towards 
suspension cells over that of adherent cell lines, as well as increases in caspase-3 activity 
and more consistent oxidative stress.  
Introduction 
Aziridinomitosenes (AZMs) are organic compounds structurally related to the 
mitomycin family of chemotherapeutic agents.  The original synthesis and 
characterization of AZMs was accomplished through reduction-oxidation reactions of 
mitomycin B (MB) and N-methyl mitomycin A (NMA).1 As such, AZMs possess similar 
structural features including the presence of a tetracyclic core featuring an aziridine ring.  
The key distinction occurs with the departure of the functional group from carbon 9a and 
deprotonation at C9, leaving a double bond between carbons 9 and 9a in AZMs (Figure 
2.1).2-4   
 
Figure 2.1 Structures of Mitomycin C and a generic AZM. Partial carbon 
numbering scheme is displayed on MC and is consistent with the AZM architecture. 
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Figure 2.2 AZMs with appreciable biological activity. Structural depiction of 
some AZMs investigated that exhibit biological activity.5-7 
Early investigations into the biological properties of AZMs were conducted 
primarily through the conversion from a corresponding mitomycin, followed by 
alterations to the C7 functional group or methylation of the aziridine nitrogen (Figure 
2.2).1,5-7  Of several AZMs, 1 was found to display similar properties to mitomycins, 
including broad spectrum bactericidal action and anti-tumor properties.1,5  Antimicrobial 
activity against gram positive bacteria was shown by 2, but it had limited effects on gram 
negative bacteria.5  Similar activity to mitomycins was observed in 4 and 5, but their 
measured responses required much larger dosages than MC.  Similarly, while AZM 6 
was more effective than MC at increasing the life span of mice inoculated with P-388 
leukemia, the required AZM dose was higher than MC.7  Despite these investigations into 
the biological and biochemical activity of AZMs, detailed description of the effects of 
AZM treatment on mammalian cells has not been published.  A handful of studies have 
found AZMs capable of inducing DNA interstrand cross-linking (ICL) in vitro utilizing 
purified nucleic acids or oligonucleotides.8-11 
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Figure 2.3 Structures of synthetic AZMs investigated in this study. H/H-AZM = 
(1S, 2S)-6-desmethyl(methylaziridino)mitosane, Me/H-AZM = (1S, 2S)-6-
methyl(methylaziridino)mitosane. 
In this study, we report the evaluation of cellular toxicity of two AZMs 
synthesized in our laboratory (1S, 2S)-6-desmethyl(methylaziridino)mitosane (H/H-
AZM) and (1S, 2S)-6-methyl(methylaziridino)mitosane (Me/H-AZM) (Figure 2.3) 
against a small panel of six human cancer cell lines.10  Cellular responses caused by AZM 
treatment in Jurkat and HeLa cell lines were explored to gain better insight into potential 
mechanisms of drugs action. Due to the structural similarities of AZMs and MC, we 
hypothesized that many of the characteristics of aziridinomitosene biological activity will 
parallel that of MC.  Our approach was to measure several potential pathways that may 
contribute to drug cytotoxicity, including stimulation of oxidative stress, alterations to the 
mitochondrial membrane potential (ΔΨm), caspase-3 activation, and changes in nuclear 
morphology that would suggest apoptotic or necrotic pathways of cell death.  
A number of chemotherapeutic drugs, including MC, have been shown to lead to 
increases in oxidative stress of cells.12-21   The formation of reactive oxygen species 
(ROS) occurs naturally in cells as a by-product of the partial reduction of oxygen during 
respiration.12,22 Typically, levels of ROS are maintained in a homeostatic balance by 
interactions with cellular antioxidants (vitamin E, vitamin C, glutathione, coenzyme Q) or 
enzymatic degradation (superoxide dismutase, catalase, glutathione peroxidase).12,23  
Elevated ROS levels in the cell can exceed the reductive capacity of anti-oxidant systems, 
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leading to oxidative damage of important intracellular biomolecules such as lipids, 
proteins, and DNA. This increased oxidative damage can lead to mutations, cancer, and 
cell death.22   
The preservation of an intact ΔΨm is essential to cellular health and proper 
mitochondrial function.  The ΔΨm is involved in functions such as the production of ATP, 
formation of ROS, mitochondrial protein transfer, and mitochondrial calcium 
sequestration.24,25  Furthermore, the collapse of ΔΨm can lead to an apoptotic cellular 
death due to the release of several pro-apoptotic factors including cytochrome c and pro-
caspase enzymes.26-29 
Cells undergoing an apoptotic cellular death experience several distinct features 
including chromatin condensation, nuclear fragmentation, and formation of apoptotic 
bodies.30,31  Condensation of the nucleus has been associated with an apoptotic cellular 
death, whereas nuclear swelling is attributed to a necrotic cell death.30,32 Previously, 
incubations with MC for 24 hours lead to an increase in nuclear area, while decarbamoyl 
MC (DMC) stimulated a decrease in nuclear area, indicating variations in their cytotoxic 
pathways.32 
Many chemotherapeutic drugs induce apoptosis through either the death-receptor-
induced extrinsic pathway or mitochondria-apoptosome-mediated apoptotic intrinsic 
pathway.  Both paths result in caspase activation.33,34  In particular, caspase-3 is activated 
in both extrinsic and intrinsic pathways.  As such, it presents as a plausible enzyme to 
investigate for preliminary insight into evaluation of the apoptotic versus necrotic cellular 
death caused by H/H-AZM and Me/H-AZM.  
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Materials and Methods 
Materials 
Mitomycin C, 2’,7’-dichlorodihydrofluorescein diacetate (DCFDA), and 
5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolocarbocyanine iodide (JC-1) were 
purchased from Cayman Chemical (Ann Arbor, MI). HyClone growth media and 
penicillin/streptomycin were obtained from Thermo Scientific (Waltham, MA). Fetal 
Bovine Serum (FBS) and N-acetyl-L-cysteine (NAC) were purchased from Fisher 
Scientific (Hampton, NH).  Resazurin sodium salt was acquired from Acros Organics 
(Fairlawn, New Jersey).  Carbonyl cyanide 3-chlorophenylhydrazone (CCCP), and 
anhydrous dimethyl sulfoxide (DMSO) were obtained from Sigma (St. Louis, MO).  
Hoechst 33342 stain and EnzChek Caspase 3 Assay Kit #2 were purchased from 
Invitrogen (Carlsbad, CA). 
Cell Culture Methods and Drug Stocks 
Six different human cell lines were used to evaluate the potency of the AZMs and 
MC.  These include three suspension (Jurkat, HUT-78, HL-60) and three adherent cancer 
cell lines (HeLa, T47D, HepG2).   The Jurkat (T lymphocyte) and HuT-78 (cutaneous T 
lymphocyte) cell lines were obtained as a generous gift from Dr. Denise Wingett, Boise 
State University.  The T47D (ductal carcinoma) and HL-60 (acute promyeloblastic 
leukemia) cell lines were kindly provided by Dr. Cheryl Jorcyk, Boise State University.  
The HepG2 (hepatocellular carcinoma) cell line was a generous gift from Dr. Kristen 
Mitchell, Boise State University.  Lastly, the HeLa (cervical adenocarcinoma) cell line 
were obtained generously from Dr. Ken Cornell, Boise State University.   
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Jurkat and T47D cells were cultured in RPM1-1640 supplemented with 10% FBS 
and penicillin (100 U/mL) and streptomycin (100 µg/mL) (pen/strep).  HeLa and HepG2 
cell lines were grown utilizing Dulbecco’s Modified Eagles Medium (DMEM) containing 
10% FBS with pen/strep.  Finally, HL-60 and HUT-78 cell lines were cultured in 
Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 20% FBS and 
pen/strep.  All cell lines were grown at 37 ºC in 5% CO2. 
All three compounds (H/H-AZM, Me/H-AZM, and MC) were dissolved in 
DMSO to create concentrated drug stocks that were stored at -80 ºC prior to use.  H/H-
AZM and Me/H-AZM were synthesized in our laboratory according to previously 
reported methods.10   
Resazurin Cytotoxicity Assay 
Cells were seeded into a 96 well plate at a density of 8,000 cells/well and 
incubated at 37 ºC in 5% CO2 overnight.  For adherent cell lines, media was replaced with 
180 µL of fresh media with 10% FBS and pen/strep, and 20 µL of 10x drug stock (diluted 
in nanopure H2O) or 20 µL vehicle.  Cultures were incubated with drug for 48 hours at 37 
ºC in 5% CO2.  After 48 hours, 20 µL of 0.1% resazurin in 1x PBS was added to all wells 
(10% of the total well volume), and the culture incubated with dye for 4-24 hours to 
allow metabolic conversion of resazurin (blue) to resorufin (pink).  Fluorescence values 
(excitation 530 ± 25 nm and emission 590 ± 35 nm) were then obtained using a BioTek 
Synergy HT plate reader (BioTek, Winooski, VT).  Fluorescence data was plotted in 
GraphPad Prism using a non-linear regression with log (inhibitor) vs. response (three 
parameter) for determination of IC50 values.  Data are represented as the mean ± SEM, for 
at least three experiments. 
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Reactive Oxygen Species Assay 
The abcam “DCFDA-Cellular Reactive Oxygen Species Assay Kit (ab113851)” 
protocol was used with slight adaptations.39 Jurkat cells were harvested via centrifugation 
at 150 x g for 5 minutes, and adjusted to a density of approximately 1 x 106 cells/mL, 
after washing once with Kreb’s Ringer Bicarbonate (KRB) buffer, pH =7.4.  Cells were 
stained with 20 µM DCFDA in KRB buffer for 30 minutes at 37 ºC.  After 30 minutes, 
cells were harvested, washed once in KRB buffer, then resuspended in KRB + 10% FBS.  
Followed by an addition of 100 µL cell solution into a black 96 well plate and combined 
with 100 µL of 2x drug dilution (made in KRB + 10% FBS solution) or 100 μL KRB + 
10% FBS solution.  Fluorescence was immediately read on a Biotek Synergy HT plate 
reader (BioTek, Winooski, VT) using excitation 485 ± 20 and emission 528 ± 20 nm.  
Additional readings were then taken at three and six hours after addition of drug 
treatments.  Data was worked up in Microsoft Excel and plotted in GraphPad Prism 6 as 
the mean ± SEM, for at least three experiments. 
HeLa cells were seeded into a black 96 well plate at 2.5 x 104 cells/well and 
allowed to adhere overnight.  Media was removed; the cells were washed once with 
KRB, and were stained with 20 µM DCFDA in Kreb’s Ringer Bicarbonate Buffer for 30 
minutes at 37 ºC.  The staining solution was removed and the cells were washed twice in 
KRB Buffer and then suspended in KRB + 10% FBS.   Buffer (100 µL) was added to all 
wells and combined with either, 100 µL of 2x drug dilution (made in KRB + 10% FBS 
solution) or 100 µL KRB + 10% FBS solution.  Fluorescence was immediately read on a 
Biotek Synergy HT plate reader (BioTek, Winooski, VT) using excitation 485 ± 20 and 
emission 528 ± 20 nm.  Additional readings were then taken at three and six hours post 
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drug treatments.  Data was worked up in Microsoft Excel and plotted in GraphPad Prism 
6 as the mean ± SEM, for at least three experiments. 
N-acetyl-L-cysteine Cytotoxicity Assay 
HeLa cells were seeded into a 96 well plate at a density of 8,000 cells/well and 
allowed to adhere overnight at 37 ºC in 5% CO2.  The next day, media was replaced with 
fresh 90% DMEM/10% FBS with pen/strep and cells were incubated with 5 mM N-
acetyl-L-cysteine (NAC) in complete media for 15 minutes at 37 ºC in 5% CO2.  NAC 
containing media was removed, cells were washed twice with 1x PBS, and 180 μL of 
fresh 90% DMEM/10% FBS with pen/strep added to all wells.  As presented above in 
“Resazurin Cytotoxicity Assay”, the cells were then treated with MC, H/H-AZM, and 
Me/H-AZM for 48 hours.  The cells were then treated with 20 μL of 0.1% Resazurin in 
1x PBS to all wells and incubated for 4 hours at 37 ºC in 5% CO2.  Fluorescence was then 
measured on a Biotek Synergy HT plate reader using excitation 530 ± 25 nm and 
emission 590 ± 35 nm, with sensitivity set to 35.  Data was then analyzed and worked up 
in Microsoft Excel and plotted in GraphPad Prism 6 as the mean ± SEM, for at least three 
experiments.    
Jurkat cells were harvested via centrifugation at 150 x g for 5 minutes at 4 ºC, 
washed once with complete media, and then suspended in 90%RPMI-1640/10% FBS 
with pen/strep and 5 mM NAC.  The Jurkat cells were allowed to incubate with the 5 mM 
NAC solution for one hour at 37 ºC in 5% CO2, after which time they were harvested via 
centrifugation, washing twice in complete media.29  The cells were then suspended in 
complete media and placed in a 96 well plate at a density of 8,000 cells/well at a final 
volume of 180 µL.  Drug dilutions were then added to appropriate wells in pentet, 
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allowing for untreated controls, as well as cells that were not incubated with NAC 
solution. Cells were allowed to incubate with drug for 48 hours at 37 ºC in 5% CO2.  The 
cells were then treated with 20 µL of 0.1% resazurin in 1x PBS to all wells and incubated 
for 24 hours at 37 ºC in 5% CO2.  Fluorescence was then measured on a Biotek Synergy 
HT plate reader using excitation 530 ± 25 nm and emission 590 ± 35 nm, with sensitivity 
set to 35.  Data was then analyzed and worked up in Microsoft Excel and plotted in 
GraphPad Prism 6 as the mean ± SEM, for at least three experiments.  
Mitochondrial Membrane Potential Assay 
Changes in the mitochondrial membrane potential were assessed using the JC-1 
dye following a slight adaptation to the abcam “JC-1 Mitochondrial membrane potential 
Assay kit (ab113850)” protocol, in black clear bottom 96 well plates.24  In cells with 
intact mitochondrial membrane potential the JC-1 dye fluoresces is unable to enter the 
mitochondria and present as aggregates that fluoresce red.  Upon dissolution of 
membrane potential, JC-1 is able to enter the mitochondria as monomers (green), leading 
to a decrease in aggregate fluorescence.  The alterations in aggregate fluorescence were 
utilized in this assay.   
Briefly, Jurkat cells were harvested via centrifugation obtaining approximately 
2.5 x 107 cells, then washing once with KRB buffer at pH =7.4.  Cells were then stained 
with 1 µM JC-1 in KRB buffer in the dark for 30 minutes at 37 ºC in 5% CO2.  After 30 
minutes, cells were harvested via centrifugation, washed once in KRB buffer, and 
suspended in 5 mL of KRB + 10% FBS.  The cell solution was then seeded into a 96 well 
plate at volume of 50 μL/well and combined with 50 μL of 2x drug dilutions made in 
KRB + 10% FBS solution or 50 μL KRB + 10% FBS solution.  The plate was allowed to 
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incubate in the dark for 2 hours at 37 ºC in 5% CO2.  The fluorescence was measured 
using a Biotek Synergy HT plate reader with excitation/emission of 530/590 nm and 
sensitivity of 70.  Data was worked up in Microsoft Excel and plotted using GraphPad 
Prism 6 as the mean ± SEM, for at least three independent experiments. 
HeLa cells were seeded into a 96 well plate at 6 x 103 cells/well and allowed to 
adhere overnight.  Media was removed and cells were washed once with KRB buffer, 
followed by staining with 1 μM JC-1 dye in KRB buffer for 10 minutes at 37 ºC in 5% 
CO2.  After 10 minutes, staining solution was removed, cells were washed twice with 
KRB buffer, and 100 μL of KRB buffer + 10% FBS added to all wells.  Treatments were 
added to appropriate wells as 100 µL of 2x drug dilution or 100 µL KRB + 10% FBS 
solution.  The cells were allowed to incubate in the dark for two hours at 37 ºC in 5% 
CO2. The fluorescence was measured using a Biotek Synergy HT plate reader with 
excitation/emission of 530/590 nm and sensitivity of 70.  Data was worked up in 
Microsoft Excel and plotted using GraphPad Prism 6 as the mean ± SEM, for at least 
three experiments. 
Caspase 3 Assay 
Evaluations into caspase 3 activation were conducted using the Molecular Probes 
EnzChek Caspase 3 Assay Kit #2 following the manufacturer’s instructions.  Briefly, 1 x 
106 Jurkat or HeLa cells were seeded into 12 well plates.  Cells were then treated with 
IC50 concentrations of MC, H/H-AZM, and Me/H-AZM for 24 hours at 37ºC in 5% CO2.  
Cells were then harvested and washed with 1x PBS via centrifugation at 150 x g for 5 
minutes at 4ºC.  From here the manufacturer’s protocol was then followed. Plates were 
read on a Biotek Synergy HT plate reader using an excitation of 485 ± 20 nm and 
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emission of 528 ± 20 nm, every 5 minutes for one hour at a sensitivity of 50. Data was 
worked up in Microsoft Excel and plotted in GraphPad Prism 6. 
Nuclear Morphology Assay 
To investigate the effects of AZMs on nuclear morphology, HeLa cells were 
grown to approximately 75% confluency in sterile 24 well plates at 37ºC in 5% CO2.  
Media was replaced with fresh complete media, and 10x drug dilutions in 1x PBS were 
added to appropriate wells.  Cells were then incubated with drugs for 24 hours at 37°C in 
5% CO2.  After 24 hours, cells were washed twice with 1x PBS, followed by fixation 
with 2% paraformaldehyde in 1x PBS for 10 minutes at room temperature.  After 
formaldehyde fixation, cells were washed twice with 1x PBS, and permeabilized with 
0.1% Triton X-100 in 1x PBS for 5 minutes at room temperature.  Nuclei were then 
stained using 1.0 µg/mL Hoechst 33342 in nanopure H2O for 15 minutes at room 
temperature.  Cell nuclei were visualized and photographed on an AMG Evos fl 
microscope using the 40x objective with the DAPI filter.  Nuclear areas were measured 
using NIH ImageJ and data worked up and plotted using GraphPad Prism 6 as the mean ± 
SEM of two experiments counting over 100 nuclei for each treatment.32,47  
Results and Discussion 
Resazurin Cell Viability Assay 
The resazurin fluorescence assay is a convenient method to examine the effect of 
cytotoxic agents on cell viability and proliferation (Table 2.1, Figure 2.4).35,36 The 
reduction of the blue non-fluorescent resazurin to the pink fluorescent resorufin occurs in 
healthy cells maintaining a reducing environment.35  The results of anti-
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proliferative/cytotoxic activity assays in six human cancer cell lines (3 adherent, 3 
suspension) are summarized in Table 2.1.  All three compounds (Me/H-AZM, H/H-
AZM, MC) showed anti-proliferative effects against the six cancer cell lines that were 
examined, with drug IC50 values ranging from low nanomolar to low micromolar 
concentrations.  
Me/H-AZM was identified as the most potent compound of the three.  Me/H-
AZM was most toxic in Jurkat cells with an IC50 value of 3.11 ± 0.57 nM and least toxic 
in HeLa cells (IC50 = 525 ± 242 nM).  H/H-AZM was overall the least toxic of the three, 
except in T47D cells where it showed a lower IC50 value (9.3 µM) than MC (17 µM).  In 
comparison to MC, Me/H-AZM was at least 2 fold more toxic in every cell line, while 
H/H-AZM was at least 2 fold less toxic in all cell lines except T47D and Jurkat.  
Table 2.1 Summary of drug cytotoxicity.  IC50 values are the mean ± SEM from 
three experiments.  
IC50 (nM) 
 Mitomycin C H/H-AZM Me/H-AZM 
HeLa 1,870 ± 372 6,208 ± 523 525 ± 242 
T47D 16,970 ± 1,472 9,291 ± 1,516 225 ± 78 
HepG2 2,937 ± 209 7,870 ± 701 342 ± 73 
HL-60 409.6 ± 85.5 2,033 ± 967 29.9 ± 4.8 
Jurkat 261.8 ± 70.8 218.7 ± 50.9 3.11 ± 0.57 
HuT-78 66.4 ± 33.0 131.2 ± 47.9 23.7 ± 16.5 
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Figure 2.4 Antiproliferative activity of AZMs and MC.  Representative results of 
investigating drug antiproliferative effects against four cell lines: A) HeLa, B) 
HepG2, C) Jurkat, and D) HuT-78.  Relative fluorescence was calculated by 
dividing the average fluorescence of drug treated cells by the average untreated 
value, and multiplied by 100 to obtain a relative percent to untreated samples. 
Points represent the mean (± SEM) of three experiments.   
The increased potency of Me/H-AZM may be due to preservation of the methyl 
group at C6, lack of a hydrophilic amine group at C7, and methylation of the aziridine 
ring (Figure 2.3) that may help to increase its lipophilicity and allow for more facile 
passage through membranes and into cells.  In addition, the presence of an electron 
donating methyl group on the quinone ring may help to preserve the electrophilic 
integrity of the AZM, stabilizing the molecule for reactions with cellular nucleophiles.  
On the other hand, electron deficiencies at carbon 6 and 7 in H/H-AZM provide 
additional electrophilic sites that may be reactive and lead to reduced drug stability and 
lower activity in vitro.  Nucleophilic addition at these locations shortly after introduction 
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into the cellular environment may hinder the cytotoxicity or allow it (H/H-AZM) to 
become sequestered by cellular nucleophiles prior to reaching a cellular target of 
significance.  
Reactive Oxygen Species Assay  
Due to the presence of a quinone moiety in the AZM structure, the potential for 
generation of ROS is highly plausible.  Other quinone containing compounds, including 
the mitomycins have been found to increase levels of ROS.12,14,15  MC itself has been 
shown to increase the production of hydrogen peroxide, superoxide anion, and hydroxyl 
radicals.13-18,20  The cell permeable dye, 2’7’-dichlorofluoresceine diacetate (DCFDA), 
has been used as a probe to evaluate the level of oxidative stress within cells.19  
Previously, DCFDA has been used to examine changes in oxidative stress due to MC 
treatment of MCF-7 cells under both normoxia and hypoxia conditions.21   
Using DCFDA as a probe, H/H-AZM treatment of both Jurkat and HeLa cell lines 
was found to increase ROS over 4-5 fold relative to untreated cells (Figure 2.5).  
Responses to Me/H-AZM varied depending on the cell line.  In Jurkat cells, Me/H-AZM 
treatment stimulated a greater than 4 fold increase in ROS over untreated cells.  Me/H-
AZM treatment of HeLa cells stimulated a less drastic ROS response, with only a ~2 fold 
increase relative to untreated cells.  In both cell lines, the measured oxidative stress 
attributed to MC treatment was essentially equivalent to the levels detected in untreated 
cells.  Results from MC treatment appear to be consistent with the studies performed in 
MCF-7 breast cancer cells using DCFDA as the oxidative stress probe under normoxia.21 
The additional electrophilic sites located at the C6/7 sites in H/H-AZM may allow 
for the reactions with intracellular antioxidants.  H/H-AZM has been shown to react more 
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quickly than Me/H-AZM with thiols, such as glutathione (unpublished results).  This 
interaction of H/H-AZM with thiols may lead to a reduction in intracellular glutathione 
levels, thus lowering the ability of the cell to combat oxidative stress.  A similar but 
limited effect may be present in Me/H-AZM, as it also possesses an additional 
electrophilic site with a functional group vacancy at carbon 7.  Me/H-AZM has also been 
shown to be reactive with thiols (unpublished results), which may explain the increased 
oxidative stress observed in Me/H-AZM treated cells.   
 
Figure 2.5 Oxidative stress responses in drug treated cells. Jurkat and HeLa cells 
were labeled with DCFDA for 30 minutes prior to addition of drug.  Fluorescence 
measurements (ex 485 nm/em 528 nm) were made at 3 and 6 hours post drug 
addition.  Relative fluorescence was calculated by dividing the average fluorescence 
of drug treated cells by the average untreated value, and multiplied by 100 to obtain 
a relative percent to untreated samples.  Data shown is the mean ± SEM of three 
experiments (n = 9) A) Jurkat cells 3 hours post drug addition, B) Jurkat cells 6 
hours post drug addition, C) HeLa cells 3 hours post drug addition, D) HeLa cells 6 
hours post drug addition.  
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N-acetyl Cysteine Cytotoxicity Assay 
N-acetyl-L-cysteine (NAC) is a precursor to glutathione, a cellular antioxidant 
used to combat ROS.  Glutathione exists as the most prevalent low molecular weight 
thiol in mammalian cells. It is present in two forms GSH (reduced) or GSSG (oxidized), 
with the reduced form occurring at concentrations 10-100 fold higher than the oxidized 
form.22,23  NAC protects against intracellular oxidative stress by scavenging radicals.38,27  
Pretreatment with 5 mM N-acetyl-L-cysteine was used to evaluate the relationship 
between oxidative stress and AZM induced cell death based on the premise if a major 
pathway to cytotoxicity is caused by increased oxidative stress, NAC should provide an 
additional antioxidant supply to combat the excess formation of free radicals, leading to 
decreased toxicity under AZM treatment. 
Pretreatment with 5 mM NAC, Jurkat cells did not provide a protective effect 
against MC and Me-H/AZM treatments, with calculated IC50 values of the non-pretreated 
and NAC pretreated experiments falling within experimental errors of each other (Figure 
6).  H/H-AZM experiences a diminished cytotoxicity after pre-treatment with NAC.  
Based on the calculated IC50 values between the NAC pretreated groups and non-NAC 
pretreated groups, NAC exerts a protective effect upon H/H-AZM in Jurkat cells.  
Previous reports revealed a protective effect with NAC pre-treatment in epidural scar 
fibroblasts, with inhibition of MC induced apoptosis.38   
In HeLa cells, results were inconsistent for H/H-AZM in both the presence and 
absence of NAC during this time and require further investigations.  MC retained its 
cytotoxicity with IC50 values falling within experimental error of each other for the NAC 
pre-treated and cells, which were not pre-treated.  Me/H-AZM toxicity appeared to 
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increase slightly with NAC pre-treatment, with a calculated IC50 168.4 ± 27.8 nM.  This 
increased toxicity may result from activation of the AZM through nucleophilic attack of 
the thiol at the C7 position.  Previous studies have shown that mitomycin A (MA) and 
MC can undergo reductive activation with thiols including glutathione to form DNA 
cross-links.40,41 
 
Figure 2.6 NAC pre-treatment and Resazurin Drug Treated Curves. Jurkat cells 
were either pretreated with 5 mM NAC for 1 hour + drug treatment (A), or drug 
treated (B).  HeLa cells were either pretreated with 5 mM NAC for 15 minutes + 
drug treatment (C), or drug treated (D), H/H-AZM not shown as results were 
inconsistent.  Cells in fresh media were then seeded into a 96-well plate at 8,000 
cells/well and treated with drug for 48 hours.  After 48 hours, 20 µL of 0.1% 
resazurin in 1x PBS was added to all wells.  Cells were allowed to incubate with 
resazurin solution for 4-24 hours.  Plates were then read using an excitation 530 ± 25 
nm and emission 590 ± 35 nm. Data is a representation of the mean ± SEM of three 
experiments, n = 5, 1 x 10-12 M was considered the concentration at which there was 
not a drug effect for the untreated controls.  
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Mitochondrial Membrane Potential Assay 
A breakdown in the ability to maintain the mitochondrial membrane potential can 
lead to excess production and leakage of ROS into the cytoplasm.  Due to the increased 
levels of oxidative stress caused by H/H-AZM and Me/H-AZM, as measured by the 
DCFDA assay, a disruption of ΔΨm would likely be the greatest in AZM treated samples.  
An alteration in the ΔΨm of Jurkat and HeLa cells were found to occur after two hours 
with MC, H/H-AZM, and Me/H-AZM treatments (Figure 2.7).  This was observed 
through the fluorescence decrease in aggregates of the cationic, lipophilic JC-1 dye.  MC 
has been previously shown to lead to changes in ΔΨm in corneal endothelial cells after 24 
hour treatment.42  
 
Figure 2.7 Mitochondrial Membrane Potential. A) Jurkat and B) HeLa cells 
were incubated with 1 µM JC-1 in KRB buffer for 30 or 10 minutes respectively, at 
37ºC in %5 CO2.  JC-1 aggregate fluorescence was then read at 2 hours post drug 
addition using ex/em of 530/590 nm and plate reader sensitivity of 50.  Plates were 
incubated at 37ºC in %5 CO2 in the dark between readings. A) Jurkat cells; B) 
HeLa cells. Data shown is the mean ± S.E.M of three experiments, n = 9.  
At lower concentrations, H/H-AZM treated aggregate fluorescence remained 
fairly constant, at around 70% of the untreated HeLa cells.  MC treatments led to 
decreases in JC-1 aggregate fluorescence in each cell line, remaining fairly constant at 
each concentration.  Previous studies in other cell lines have shown that MC treatment 
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leads to changes in the ΔΨm, and this result is consistent with our MC investigations in 
the Jurkat and HeLa cell lines.42 
Me/H-AZM was the most effective in altering JC-1 aggregation as indicated by 
the decrease in fluorescence to about 50% of the untreated controls in both cell lines.  
H/H-AZM presented with similar decreases to MC in Jurkat cell lines, decreasing 
aggregate fluorescence to approximately 80% of the untreated control.  In HeLa cells, 
H/H-AZM decreased JC-1 aggregate fluorescence similar to Me/H-AZM, around 50% of 
untreated cells at higher concentrations.   
Both AZMs lead to a decrease in JC-1 aggregate fluorescence in each cell line.  
This result is consistent with our expectation that due to the increased levels of oxidative 
stress measured in the DCFDA assay, it is likely there will be alterations to the 
mitochondrial membrane potential.  It is unclear if the mitochondria is a direct target of 
AZMs but evidence supports that this organelle is affected by treatment with these 
compounds.  
Caspase 3 Activation 
Caspase-3 is a downstream effector caspase activated through two pathways in 
apoptotic cell death.  MC induced activation of caspases has been documented 
previously, including the stimulation of caspase-3.43-45 After 24 hours of incubation, all 
compounds were found to activate caspase-3 more than the untreated controls in the 
Jurkat cell lines (Figure 2.8).  MC (262 nM) had the most substantial effect, followed by 
H/H-AZM (220 nM), while Me/H-AZM (3 nM) produced the lowest levels of caspase-3 
activation of the three compounds.  In the HeLa cell line, MC (1.87 µM) was the only 
drug that significantly activated caspase-3 over that of the untreated sample.  Treatments 
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with H/H-AZM (6.2 µM) and Me/H-AZM (525 nM) led to caspase-3 activity similar to 
that observed in the untreated samples.   
 
Figure 2.8 Caspase 3 activation by 24 hour treatment.  A) Jurkat and B) HeLa 
cells were treated with IC50 concentrations of drug for 24 hours. Cells were then 
subject to the protocol outlined in materials and methods. Data is presented as the 
mean ± SEM of three experiments, n = 18 for Jurkat cells, n = 9 for HeLa cells. * 
denotes p < 0.05 as determined by one-way ANOVA when compared to untreated 
sample. 
Activation of caspase-3 is consistent with forms of apoptotic cell death.  The 
increased levels of caspase-3 displayed in treatments with MC, H/H-AZM, and Me/H-  
AZM signify a likelihood of apoptotic cell death, rather than necrosis.  Since caspase-3 is 
an effector caspase activated via both apoptotic pathways, further inquiry into which of 
the initiator caspases become activated with AZM treatment is needed in order to develop 
a clear understanding of whether AZM induced apoptosis follows the death-receptor-
induced extrinsic or mitochondria-apoptosome-mediated apoptotic intrinsic pathway.33,34 
Nuclear Morphology Assay 
Apoptotic cells undergo fragmentation of chromosomes, leading to condensation 
of the nucleus.  During necrotic cell death, nuclei experience swelling as the cell loses its 
membrane integrity and is no longer able to regulate its osmotic balance.30,46  Nuclear 
swelling as a result of 10 μM MC has been observed previously in cells treated for 24 
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hours.  In the same study, the decarbamoyl MC derivative (DMC) was found to lead to 
nuclear condensation with the same dosage.32  In this study, HeLa nuclear areas were 
assessed using the DNA fluorescent stain Hoechst 33342 and NIH ImageJ after 24 hour 
treatment (Figure 2.9).32,32 
Treatment with 10 µM H/H-AZM and MC lead to a significant increase in HeLa 
nuclear area when compared to the untreated control.  After 24-hour treatment with 10 
μM Me/H-AZM, a majority of the HeLa cells became detached from the plate making it 
difficult to find remaining nuclei.  The measurable nuclei were found to be significantly 
condensed when compared to the untreated samples, likely attributed to cell death.  
However, nuclear swelling followed by cell death could have occurred well before the 24 
hour measurement, which would mean that the event was missed prior to measuring 
nuclear area.  With 1 µM treatments, both MC and Me/H-AZM produced nuclear 
swelling, while H/H-AZM treated nuclei were, on average, more condensed than the 
untreated control.  A similar pattern was observed in the 100 nM treatment groups, with 
MC and Me/H-AZM causing nuclear swelling, with no effect observed in the H/H-AZM 
treated cells.  At 10 nM, there was no observable drug treated effect as nuclear areas were 
consistent with the untreated control.  The alterations in the nuclear morphology imply 
that MC and Me/H-AZM may induce a similar mechanism of cell death with observed 
nuclear swelling at 1 µM and 100 nM concentrations.  Of particular curiosity was the 
nuclear condensation witnessed in HeLa cells treated with 1 µM H/H-AZM, after 
observed swelling in the 10 µM treatments.  An observed increase in nuclear area 
displayed by both AZMs and MC implies that they follow a similar mechanism of action   
in HeLa cells.  
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Figure 2.9 HeLa Cell Nuclear Morphology and Area. HeLa cells were grown to 
approximately 75% confluency in 24 well plates at 37 ºC in 5% CO2.  They were 
then either left untreated, or treated with MC, H/H-AZM, or Me/H-AZM for 24 
hours.  The cells were fixed in 2% paraformaldehyde, permeabilized using 0.1% 
Triton X-100, then stained with 1.0 µg/mL Hoechst 33342.  Cell nuclei were then 
visualized on an AMG Evos fl microscope using the 40x objective and DAPI filter. 
Nuclear areas were measured using NIH ImageJ.  Data is presented as the mean ± 
SEM from two experiments, n > 100 for each treatment. * denotes p < 0.05 as 
determined by one-way ANOVA when compared to untreated sample.  
Conclusion 
A widespread approach in determining the characteristics of two synthetic AZMs 
and their associated cytotoxicity was conducted.  Our initial hypothesis was that AZM 
induced cellular death follows a similar pathway to MC and there appear to be some 
parallels in the cellular effects caused by treatment with MC and AZMs.  Evaluations into 
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the potency of AZMs and MC were determined using a resazurin reduction assay to 
obtain an IC50 value in six different human cancer cell lines.35,36  Me/H-AZM was more 
efficacious in decreasing cell viability when compared to both H/H-AZM and MC across 
all cell lines.   The most drastic difference in drug toxicity was observed in T47D cells, 
where Me/H-AZM was 74 fold more potent than MC.  In contrast, H/H-AZM was the 
least effective compound in decreasing cell viability, with increased potency compared to 
MC in only the T47D cell line. 
Jurkat and HeLa cells treated with AZMs lead to increased production of ROS, 
when compared to the untreated controls.  MC induced levels of ROS, remained 
consistent with the untreated sample in each cell line, correlating well with a study in 
MCF-7 cells utilizing DCFDA.21  To evaluate whether this increased ROS production 
was a major factor in the AZM induced cell death, we employed pre-treatment with the 
oxygen radical scavenger, NAC.  Pre-treatment with NAC did not produce a significant 
decrease in Me/H-AZM or MC associated cytotoxicity in Jurkat cells.  However, NAC 
pretreatment produced a protective effect against H/H-AZM treatments in Jurkat cells.  In 
HeLa cells, NAC pre-treatment stimulated Me/H-AZM toxicity with a drop in the 
calculated IC50 value, but remained the same in MC. Results from H/H-AZM in HeLa 
cells were inconsistent and require further investigation.  These results indicate that a 
protective effect by NAC was observed in Jurkat cells treated with H/H-AZM, but not 
MC and Me/H-AZM.  Similar results were seen in HeLa cells with MC and Me/H-AZM 
treatments.  No conclusions can be drawn regarding H/H-AZM and NAC pre-treatment 
in HeLa cells.  
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Collapse of the mitochondrial membrane potential is affiliated with an apoptotic 
cell death with the release of pro-caspases and cytochrome c.25 In addition, disruption of 
the ΔΨm
 can lead to increased levels of ROS.  As a consequence to the increased ROS 
production measured by AZM treatments, attention was directed towards measuring a 
potential collapse in ΔΨm.  After two hours, a change in the ΔΨm was observed by 
treatments with all three compounds in both cell lines, with Me/H-AZM leading to the 
largest decrease in aggregate fluorescence.  H/H-AZM treatment lead to a greater 
disruption of ΔΨm in HeLa over Jurkat cells.   
The activation of caspase 3 occurs in the death-receptor-induced extrinsic 
pathway or mitochondria-apoptosome-mediated apoptotic intrinsic pathway.33 Previous 
studies have shown that MC treatment leads to activation of caspase 3.38,42-45  Treatment 
with IC50 concentrations lead to a significant increase in caspase 3 activity with all three 
drugs in Jurkat cells.  MC led to the largest increase in caspase 3 activity, followed by 
H/H-AZM and Me/H-AZM.  However, in HeLa cells only MC was shown to produce a 
significant increase in caspase-3 activity over that of the untreated controls.  
Our initial hypothesis that AZMs follow a similar pattern as MC in their cellular 
effects appeared to be moderately correct.  Similarities in their cellular effects include 
alterations in ΔΨm, caspase-3 activation, nuclear swelling by each drug in at least one 
drug concentration, and continuity of cytotoxicity after NAC pre-treatment (in Jurkat 
cells).  Deviations in AZM and MC cellular effects were observed in AZM increased 
oxidative stress, while not measured in MC treatments.  While there are some shared 
cellular effects between MC, H/H-AZM, and Me/H-AZM, there is much more work to be 
done in characterizing the many effects AZMs have in cellular treatments.   
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CHAPTER THREE: MODIFICATION OF CELLULAR DNA  
BY AZIRIDINOMITOSENES 
The ability of two synthetic aziridinomitosenes (AZMs) to modify DNA in Jurkat 
and HeLa cells was evaluated using a Hoechst 33342 fluorescent assay and modified 
alkaline Single Cell Gel Electrophoresis (COMET) assay.  The Hoechst 33342 assay 
showed that (1S, 2S)-6-methyl(methylaziridino)mitosene (Me/H-AZM) treatment 
increased cross-linkage 48 and 6 fold greater than mitomycin C (MC) in Jurkat and HeLa 
cells, respectively.  In contrast, (1S, 2S)-6-desmethyl(methylaziridino)mitosene (H/H-
AZM) only increased the cross-linkage of DNA in Jurkat cells 12.5 fold greater than MC.  
In HeLa cells, H/H-AZM sponsored DNA cross-links were approximately two fold lower 
than MC.  The modified alkaline COMET assay allows for the evaluation of DNA 
modification of a drug through the reduced migration of treated DNA.  H/H-AZM treated 
cells showed significantly less DNA migration in the modified alkaline COMET assay 
with tail extent moments of 0.7% and 59.6% of MC in Jurkat and HeLa cells, 
respectively.  Me/H-AZM tail extent moments in Jurkat and HeLa cells were found to be 
0.3% and 6.3% of MC treated cells, correspondingly.  The results of this study indicate 
that AZMs are capable of modifying DNA in in vitro cellular systems, with Me/H-AZM 
showing the most potent activity and greatest alterations to DNA.    
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Introduction 
Aziridinomitosenes (AZMs) are a class of compounds that are structurally similar 
to mitomycin chemotherapeutics.  The first synthesis, characterization, and preliminary 
biological activity of AZMs were reported in 1964.1 Further, they present as an 
intermediate in the DNA alkylating reductive activation cascade of mitomycins.2  
Structurally, AZMs differ from mitomycins by the placement of a double bond between 
carbons 9 and 9a in the AZM architecture, whereas this is a single bond in mitomycins 
(Figure 3.1).3  The double bond promotes the benzylic-like stabilization of electrophilic 
carbons 1 and 10, increasing their susceptibility to nucleophilic groups, such as the 
amines in DNA, thus leading to DNA cross-linking. 
 
Figure 3.1 Structures of mitomycin C and aziridinomitosenes. MC displays a 
partial carbon numbering scheme consistent with mitomycins and 
aziridinomitosenes.  H/H-AZM = (1S, 2S)-6-desmethyl(methylaziridino)mitosene, 
Me/H-AZM = (1S, 2S)-6-methyl(methylaziridino)mitosene. 
Of the mitomycins, MC has received the most attention and use as a 
chemotherapeutic agent.  MC has been useful as a single agent or in combination therapy 
for a variety of different cancers including local bladder, head and neck, breast, and non-
small cell lung cancers.  Despite its widespread applications, MC use is limited due to 
severe side effects such as myelosuppression or haemolytic uremic syndrome.4   
The biological activity of the mitomycins has been attributed to the formation of 
DNA-DNA interstrand cross-links (ICLs), a covalent modification between two 
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complimentary strands of DNA.5,6  Prior to forming ICLs, MC must first undergo 
chemical or enzymatic reductive activation, rendering the drug electrophilic (Figure 
3.2).5,7-11  As such, MC induced cytotoxicity has shown preference towards hypoxic 
conditions, or those favoring its reductive activation.11,12 
 
Figure 3.2 Reductive activation of MC.  Reduction of MC leads to formation of a 
mono-alkylated (blue sphere only) or bis-alkylated (both blue and red spheres) 
compound.  
The formation of ICLs with AZMs have been reported using purified synthetic or 
bacterial DNA in the presence and absence of reducing agents.14-17  Similar to MC, 
AZMs exhibit a DNA sequence preference towards 5'-CpG-3' motifs. 14-17  The synthetic 
AZM, (1S, 2S)-6-desmethyl(methylaziridino)mitosene (H/H-AZM) has been shown to 
cross-link DNA with similar frequency and specificity as MC, with alkylation occurring 
preferentially at guanine residues.13,16,17  Previous reports suggest that H/H-AZM may 
form both DNA-DNA and DNA-protein cross-links.16 In contrast to MC, H/H-AZM was 
shown to cross-link synthetic DNA in the presence of oxygen, and did not require 
activation by exogenous reductants.  Guanine nucleotides were confirmed as the 
nucleophilic species in the formation of H/H-AZM facilitated DNA ICLs.17  
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Prior investigations of DNA modification by AZMs were confined to 
demonstration of adduct formation with purified nucleic acids or oligonucleotides.  The 
current study was initiated to establish that AZMs could cause modifications to DNA in 
eukaryotic cellular environments.  We evaluated DNA modification induced by H/H-
AZM and Me/H-AZM, in HeLa and Jurkat cell lines using a Hoechst 33342 fluorescent 
DNA cross-linking and modified alkaline COMET assays.16,18,22,25,27,28 
Hoechst fluorescent DNA cross-linking studies have previously been conducted 
using Hoechst 33258 fluorescence with T7 coliphage DNA to study cross-linking agents, 
including reductively activated MC and its analogs.18-20  The premise of this assay is that 
DNA cross-links will lead to increased retention of Hoechst fluorescence after a heat 
denaturation/rapid cooling process when compared to native DNA.  Reductively 
activated MC and the decarbamoyl derivative (DMC) were found to cross-link T7 in a 
concentration dependent manner with this assay.20  Here, we apply this method to DNA 
isolated from AZM treated human cancer cells in order to determine the relative amount 
of cross-linkage that occurred using the fluorescent DNA probe Hoechst 33342.   
In its original development, the Single Cell Gel Electrophoresis (COMET) assay 
was used to identify DNA damaging agents and investigate the repair kinetics in cells.21 
Since then, variations to the COMET assay have been described that allow the detection 
of DNA cross-linking agents.  These evaluations are based on the compound’s ability to 
decrease the electrophoretic mobility of DNA when combined with DNA damaging 
agents.22-24,26-28   In this study, as in previous studies with MC, we use a similar modified 
alkaline COMET assay to measure DNA cross-linkage in MC or AZM treated that were 
subsequently exposed to the DNA damaging agent hydrogen peroxide.25  
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Materials and Methods 
Materials 
MC was purchased from Cayman Chemical (Ann Arbor, MI).  Hoechst 33342 
was obtained from Invitrogen (Eugene, OR).  A 10,000x SYBR Green solution was 
aquired from Molecular Probes (Eugene, OR).  HyClone growth media (RPMI-1640 and 
Dulbecco’s Modified Eagles Medium (DMEM)) and penicillin/streptomycin solution 
were obtained from Thermo Scientific (Waltham, MA). Fetal Bovine Serum (FBS) was 
purchased from Fisher Scientific (Hampton, NH).  Blood and Cell Culture Mini Kit was 
obtained from Qiagen (Hilden, Germany).  The CometAssay Kit was purchased from 
Trevigen (Gaithersburg, MD).  
Cell Culture 
Jurkat and HeLa cell lines were obtained as a generous gift from Dr. Denise 
Wingett, Dr. John Rasmussen, and Dr. Ken Cornell at Boise State University.  Jurkat 
cells were cultured in RPMI-1640 supplemented with 10% FBS, penicillin (100 U/mL), 
and streptomycin (100 µg/mL).  HeLa cells were cultured in DMEM with 10% FBS, 
penicillin (100 U/mg), and streptomycin (100 µg/mL). Cell lines were grown at 37 ºC in 
5% CO2 atmosphere.    
Jurkat and HeLa Cell DNA Isolation 
Jurkat and HeLa genomic and mitochondrial DNA were isolated together using 
the Qiagen DNA and Blood Mini Kit according to the manufacturer’s recommendations 
for “Tissue” isolation.  This protocol allows for the isolation of mitochondrial DNA as 
well as genomic DNA.29  Prior to DNA isolation, Jurkat and HeLa cells were grown in 
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T25 flasks until approximately 90% confluent or ~5-6 x 106 cells were available.  Cells 
were then treated with vehicle (1x PBS) or 10 µM MC, H/H-AZM, or Me/H-AZM for 
one hour.   After one hour, cells were harvested, washed twice in 1x PBS, and the DNA 
isolated according to the manufacturer’s directions for “Tissue” DNA isolation.  DNA 
concentrations were determined using a SYBR green fluorescence assay.30 
Hoechst 33342 DNA Cross-Linking Assay 
The following protocol is an adaptation to cross-linking assay presented by 
Penketh, Shyam, and Sartorelli.18 DNA utilized in these experiments were isolated as 
outlined above.  Samples for the assay were prepared in the dark by combining isolated 
cellular DNA (3,750 ng) with 300 µL of 1.0 µg/mL Hoechst 33342 in nanopure H2O. The 
total volume was brought to 3 mL with 0.5x TE buffer.  Fluorescence (ex 360 nm/em 460 
nm) of a 2 mL portion of each sample was then read on a Varian Cary Eclipse 
Fluorimeter (Palo Alto, CA).  A solution of 2,700 µL 0.5x TE + 300 µL 1.0 µg/mL 
Hoechst 33342 was used as a blank.  After the initial readings, the retention of 
fluorescence was measured after subjecting samples to a heat/chill process as follows: 5 
minutes in a 96-98°C water bath, immediate chilling in an ice/water bath for 5 minutes, 
followed by incubation in a room temperature water bath for 5 minutes. The fluorescence 
measurement was repeated and the cross-linked fractions were determined using 
Equation 1:   
Cross-linked fraction  =  
𝐸𝐴
𝐸𝐵
   −  𝐶𝐴
𝐶𝐵
1  −  𝐶𝐴
𝐶𝐵
               Equation 1 
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Where, CA = fluorescence of control sample after heat/chill, CB = fluorescence of control 
sample before heat chill, EA = fluorescence of experimental sample after heat/chill, and  
EB = fluorescence of experimental sample before heat/chill. 
Data was analyzed in Microsoft Excel (Redmond, WA) and GraphPad Prism 
(www.graphpad.com). Values were presented as the mean ± SEM of two independent 
DNA isolations with measurements conducted in triplicate for each isolation.  
Modified Alkaline COMET Assay 
The alkaline COMET Assay was performed according to the manufacturer’s 
protocol (Trevigen, Gaithersburg, MD) with minor modifications.  Briefly, Jurkat and 
HeLa cells were harvested, washed once with complete media, and reconstituted to a 
final density of 1 x 105 cells/mL (Jurkat) or 2 x 105 cells/mL (HeLa) using complete 
media in sterile 1.5 mL micro-centrifuge tubes.  Cells were then either treated with a final 
concentration of either 10 µM MC, H/H-AZM, Me/H-AZM, or 1x PBS for one hour at 
37 °C in 5% CO2 with agitation every 15 minutes.  After one hour, the cells were 
harvested via centrifugation, washed once in 1x PBS (Ca2+ and Mg2+ free), then 
resuspended in 100 µM hydrogen peroxide in 1x PBS for 20 minutes (Jurkat) or 30 
minutes (HeLa) at 4°C.  Next, cells were harvested via centrifugation (5 min, 150 x g 
(Jurkat), 250 x g (HeLa)), washed twice, and suspended in 1 mL of 1x PBS (Ca2+ and 
Mg2+ free).  A 50 µL portion of the cell suspension was then combined with 300-500 μL 
of 37 °C low melting point agarose.  The resulting solution was mixed by inversion 
several times and a 50 μL portion spread evenly on the COMET slide.  COMET slides 
were then allowed to solidify at 4 °C for 30 minutes in the dark, after which they were 
submerged in lysis solution overnight at 4 °C in the dark.  The following day, the slides 
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were removed from the lysis solution and submerged in a freshly prepared alkaline DNA 
unwinding (pH >13) solution for 20 minutes at room temperature in the dark.  Slides 
were then subjected to electrophoresis (20V, ~300 mA) in freshly made alkaline 
electrophoresis solution for 30 minutes at 4 °C.  After electrophoresis, the slides were 
rinsed twice in fresh deionized water for 5 minutes, followed by a third washing in 70% 
ethanol for 5 minutes.  Slides were then dried at 37 °C for 15 minutes, followed by 
staining with 1x SYBR Green solution in 1x TE (pH 8.0) for 30 minutes at room 
temperature in the dark.  Slides were then briefly washed in deionized water and dried at 
37°C for approximately 1-2 hours.  COMETS were visualized and images captured using 
an AMG Evos fluorescent microscope (Mill Creek, WA) using the 10x objective and 
GFP filter.  Analysis for tail extent moment was performed using the OpenComet plugin 
for ImageJ (NIH), and tail extent moments (mean ± SEM) plotted in GraphPad Prism 
6.31,32  
Results 
Hoechst 33342 DNA Cross-Linking Assay 
The thermal denaturation process followed by rapid cooling causes mismatching 
in the base pairing of DNA leading to a decrease in fluorescence.  The Hoechst 
fluorophores preferentially bind to A-T rich regions through the minor groove of DNA.33  
When bound to double stranded DNA (dsDNA), Hoechst stains exhibit an increased 
fluorescence when compared to single stranded DNA (ssDNA).  Covalent cross-links in 
the DNA act as anchor points, decreasing the mismatched base pairing during rapid 
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renaturation.  Thus, DNA with more cross-linking will exhibit increased retention of 
fluorescence after the heat/chill process.18   
The relative fraction of cross-linked DNA created by MC and AZMs were 
determined using isolated DNA from drug treated Jurkat and HeLa cells (Table 3.1, 
Figure 3.3).  When Jurkat and HeLa cells were treated with 10 µM Me/H-AZM for one 
hour, there was a significant increase in the amount of cross-linked DNA when compared 
to MC and H/H-AZM treatment.  The fraction of cross-linked fractions was calculated at 
0.39 (± 0.01) and 0.29 (± 0.01) for Me/H-AZM treated Jurkat and HeLa cells, 
respectively.  The cross-linking sponsored by Me/H-AZM treatment was 48 fold greater 
than MC treatment in Jurkat cells, and 6 fold higher than MC treatment in HeLa cells. 
Similarly, the fraction of cross-linked DNA was higher in H/H-AZM treated Jurkat cells 
than in HeLa cells.  In the Jurkat cell line, H/H-AZM treatment increased the fraction of 
cross-linked DNA 12.5 fold greater than MC treatment.  In contrast, MC treatment of 
HeLa cells resulted in a 1.7 fold increase in cross-linked DNA compared to H/H-AZM 
treatment.  This suggests that Jurkat DNA is more susceptible to H/H-AZM sponsored 
cross-linkage.   
Table 3.1 Hoechst 33342 Assay for Cross-Linked DNA.  Data presented is the 
calculated mean fraction of cross-linked DNA (± SEM) for two experiments, n = 6. 
Fraction of Cross-Linked DNA 
Drug (10 µM) Jurkat cells HeLa cells 
Mitomycin C 0.008 ± 0.003 0.045 ± 0.004 
H/H-AZM 0.10 ± 0.03 0.026 ± 0.007 
Me/H-AZM 0.39 ± 0.01 0.29 ± 0.01 
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Figure 3.3 Hoechst 33342 DNA Cross-linking.  A) Jurkat and B) HeLa cellular 
DNA was isolated after one hour treatment with either 10 µM mitomycin C, H/H-
AZM, or Me/H-AZM.  The fraction cross-linked of isolated DNA found in three 
drug treatments of A) Jurkat cells and B) HeLa cells was measured using Hoechst 
33342 fluorescence. Data is presented as mean ± SEM of two experiments, n = 6, * 
denotes p < 0.05, by one-way ANOVA, when compared to Mitomycin C. 
Modified Alkaline COMET Assay 
The modified alkaline COMET assay provides the ability to investigate the extent 
of drug induced DNA cross-linking in individual cells.  The alkaline COMET assay 
allows for visualization and quantification of DNA strand breakage, or damage and repair 
in single cells induced by DNA damaging agents.19,26  The assay does not readily 
ascertain the ability to detect DNA alkylation events such as DNA interstrand, 
intrastrand, or DNA-protein cross-links.26  Treatment with a genotoxic agent such as 
hydrogen peroxide induces DNA strand breaks that increases the electrophoretic mobility 
of DNA and results in the appearance of an elongated “tail” in the electropherogram.  
Agents that sponsor DNA cross-linking prior to hydrogen peroxide exposure ultimately 
hinder migration of DNA during electrophoresis by decreasing the amount of strand 
breaks that can occur. 22,23,25,26  This leads to a decreased tail length in the 
electropherogram when compared to cells only treated with hydrogen peroxide.22,28  The 
“tail extent moment” is calculated by multiplying tail length by the measured amount of 
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DNA in the tail.26  Previously, treatment of bladder cancer cell lines with MC was 
reported to cause DNA cross-linkage that resulted in decreased γ-radiation induced DNA 
strand breakage in the COMET assay.  The DNA in the assay displayed decreased 
electrophoretic mobility, and a decreased "tail" in the electropherogram.26   This type of 
modified alkaline COMET assay has also been used to demonstrated DNA cross-linkage 
by platinum containing chemotherapeutics, such as oxaliplatin and satraplatin.28 
Results from our modified alkaline COMET assay indicate that treatment of 
Jurkat and HeLa cells with 10 µM drug treatment (MC, H/H-AZM, and Me/H-AZM) for 
one hour results in decreased electrophoretic mobility of the DNA (Figures 3.4 and 3.5).  
Jurkat cells treated with H/H-AZM and Me/H-AZM produced mean tail extent moments 
of 0.45 ± 0.07 and 0.17 ± 0.03, respectively.  These tail extent moments were 
significantly reduced relative to MC treatment (Figure 3.4, panel F).  Tail extent moments 
for MC were found to be 64.06 ± 7.04 in Jurkat cells, compared to that of 69.82 ± 5.50 
for the 100 µM H2O2 treated control, indicating that MC was poorly effective at causing 
DNA cross-linkage under the aerobic conditions used in the assay.  The AZMs appear to 
reduce tail extent moments at least 142 fold greater than MC in Jurkat cells.  
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Figure 3.4 Modified Alkaline COMET assay of Jurkat cells. Jurkat cells were 
treated with either MC or AZM for one hour at 37ºC in 5% CO2 atmosphere 
followed by exposure to 100 µM H2O2 for 20 minutes at 4 ºC to induce DNA strand 
breaks. Controls consisted of cells that received no drug (minimal DNA strand 
breaks), or received only H2O2 treatment (maximal DNA strand breaks).  Panels 
show fluorescence micrographs of Jurkat cell electropherograms. Panel A) Vehicle 
w/o 100 µM H2O2; B) Vehicle + 100 µM H2O2; C) 10 µM mitomycin C + 100 µM 
H2O2; D) 10 µM H/H-AZM + 100 µM H2O2; E) 10 µM Me/H-AZM + 100 µM H2O2.  
Panel F) Plot of Jurkat cell tail extent moment. Tail extent moments are expressed 
as the mean ± SEM of two experiments (n > 50 cells per treatment). * Denotes p < 
0.05 by one-way ANOVA, when compared to 100 µM H2O2 treated sample. 
In contrast to Jurkat cells, HeLa cells appeared to be less sensitive to drug induced 
DNA cross-linkage (Figure 3.5).  Tail extent moments in HeLa cells were the lowest in 
the Me/H-AZM treatment group (5.72 ± 0.73), followed by H/H-AZM treatment (53.77 ± 
3.24).  Both AZMs produced significant reductions in tail extent moments relative to the 
100 µM H2O2 control.  Me/H-AZM and H/H-AZM produced tail extent moments that 
were 15.8 and 1.7 fold lower, respectively, than MC treatment.  Similar to the findings in 
Jurkat cells, MC treatment of HeLa cells produced tail extent moments (90.25 ± 4.17) 
that were insignificant when compared to the 100 µM H2O2 control (101.5 ± 4.6).  Both 
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AZMs were able to significantly reduce the tail extent moments in HeLa cells to a greater 
extent than MC, with Me/H-AZM and H/H-AZM, 15.8 and 1.7 fold lower tail extent 
moments respectively (Figure 3.5).  
 
Figure 3.5 Modified Alkaline COMET assay of HeLa cells. HeLa cells were 
treated with either MC or AZM for one hour at 37ºC in 5% CO2 atmosphere 
followed by exposure to 100 µM H2O2 for 30 minutes at 4 ºC to induce DNA strand 
breaks. Controls consisted of cells that received no drug (minimal DNA strand 
breaks), or received only H2O2 treatment (maximal DNA strand breaks).  Panels 
show fluorescence micrographs of Jurkat cell electropherograms. Panel A) Vehicle 
w/o 100 µM H2O2; B) Vehicle + 100 µM H2O2; C) 10 µM mitomycin C + 100 µM 
H2O2; D) 10 µM H/H-AZM + 100 µM H2O2; E) 10 µM Me/H-AZM + 100 µM H2O2.  
Panel F) Plot of HeLa cell tail extent moment. Tail extent moments are expressed as 
the mean ± SEM of two experiments (n > 50 cells per treatment). * Denotes p < 0.05 
by one-way ANOVA, when compared to 100 µM H2O2 treated sample. 
Discussion and Conclusion 
Results from the Hoechst 33342 cross-linking assay and modified alkaline 
COMET assay provide evidence that H/H-AZM and Me/H-AZM create DNA cross-links 
in Jurkat and HeLa cells after one hour of treatment in an aerobic environment.  Me/H-
AZM was more potent than H/H-AZM, particularly in Jurkat cells.  MC treatment under 
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aerobic conditions resulted in insignificant DNA modification, which would be expected 
based on prior reports that demonstrated enhanced activation of MC for DNA cross-
linking under anaerobic/reducing conditions.    
The modified alkaline COMET assay provided insight into the occurrence of 
DNA alkylation events, although it does not distinguish between DNA-DNA or DNA-
protein cross-links.  However, the observed decreases in tail extent moments further 
support that cellular DNA is a target of AZM treatment that produces modifications 
(cross-linkages) that stabilize the structure and interfere with subsequent strand break 
formation.  The differences in tail extent moments displayed by H/H-AZM in Jurkat and 
HeLa cells also provides evidence that Jurkat cell DNA is more vulnerable to DNA 
alkylation.  These findings correspond well with the results of the Hoechst 33342 assay 
that showed that the fraction of cross-linked DNA was greater in AZM treated Jurkat 
cells compared to similar treatment of HeLa cells.   
The Hoechst 33342 cross-linking assay utilizes DNA isolated from cells that have 
been treated with both RNAse-A and Proteinase K prior to purification.  Since these 
enzymes act to cleave RNA and proteins and results in their removal from the system, the 
Hoechst assay should be more specific for the presence of DNA-DNA cross-links.33,35  
Interstrand cross-links are probably the most likely even since they would stabilize the 
double stranded DNA that would bind the Hoechst dye and result in retained fluorescence 
in the assay.18,34  The formation of DNA-DNA cross-links by H/H-AZM is consistent 
with the formation of DNA-DNA interstrand cross-link formation reported by other 
investigators that examined AZM treatment of purified (cell free) radiolabelled DNA and 
UVrABC nuclease.16,17 
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AZM mediated DNA protein cross-links should still be considered as a relevant 
alkylation event, although not specifically measured here.  While treatment with H/H-
AZM and Me/H-AZM both produced similar reductions in tail extent moments in the 
COMET assay, the fraction of cross-linked DNA produced by Me/H-AZM treatment was 
approximately four fold greater as measured in the Hoechst assay, suggesting that other 
alkylation events are occurring besides DNA-DNA cross-links.  The susceptibility to 
nucleophilic attack in H/H-AZM is present at four potential electrophilic locations at C1, 
C6/7, and C10.  Prior reports by the Vedejs group demonstrated that H/H-AZM treatment 
resulted in the formation of high molecular weight DNA adducts that were tentatively 
attributed to AZM mediated DNA-protein cross-links.16  Preliminary unpublished 
investigations within our laboratory have indicated that H/H-AZM is capable of forming 
DNA-protein cross-links with bovine serum albumin (BSA).  The high intracellular 
concentration of protein, and particularly the presence of numerous DNA associated 
proteins (e.g., histones, etc.) that contain nucleophilic amine groups that could react with 
AZMs, suggest that the formation of a DNA-protein cross-link is highly probable.  While 
additional work is required for the identification and subsequent characterization of AZM 
induced intracellular DNA-protein cross-links, the modified alkaline COMET assay 
could lend supplementary insight.  While the alkaline method utilized in these 
experiments is reported to remove histones from DNA during the lysis process, this step 
occurs after AZM treatment, which leads us to postulate that DNA-protein cross-links 
(e.g., DNA-histone) may be retained in the assay.  Further investigations should be 
directed towards measurement of the capability of AZMs to mediate DNA-protein cross-
links and characterization of the alkylated adduct.  
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The increased DNA alkylation displayed by Me/H-AZM over H/H-AZM may be 
attributed to conservation of the methyl group at C6 that occurs throughout the A, B, and 
G-type mitomycins.36 The methyl group is the sole structural difference between Me/H-
AZM and H/H-AZM.  Yet, this simple alteration results in a remarkable increase in 
cytotoxicity and DNA modification in two different cell lines.  The methyl group may 
help to increase the lipophilicity of the aziridinomitosene that subsequently improves its 
cellular uptake and retention and increases its intracellular concentration.  More likely, 
however, the presence of the inductive electron donation from the methyl group leads to 
increased stabilization of the electrophilic sites, resulting in a more stable DNA 
alkylating compound.  Furthermore, the methyl group at C6 may sterically hinder 
nucleophile accessibility to the quinone ring, thus improving the half-life of the AZM by 
preventing non-productive reactions with other biomolecules outside the context of the 
DNA.  
In conclusion, two synthetic AZMs produced within our lab were able to modify 
DNA in a cellular setting with similar or increased efficacy relative to MC, as indicated 
by Hoechst 33342 fluorescence and modified alkaline COMET assays.  The addition of a 
methyl group at C6 in the AZM skeleton (Me/H-AZM) led to increased DNA cross-
linking in both Jurkat and HeLa cell lines.  Future experiments will be directed towards 
determining the DNA alkylating abilities of additional AZM analogs with chemical 
modification at the C6, C7, and C10 positions.  Furthermore, additional studies to 
characterize and confirm DNA-AZM-protein cross-links and DNA-AZM-DNA cross-
links from treated cells are being explored.    
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